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ABSTRACT   
Elastin-like peptide (ELP) fusions promote therapeutic delivery and efficacy. Recombinant 
proteins, like neurotrophins, lack bioavailability, have short in vivo half-lives, and require high 
manufacturing costs. Fusing recombinant proteins with genetically encodable ELPs will increase 
bioavailability, enhance in vivo solubilization, as well as provide a cost-effective method for 
purification without the need for chromatography. During expression of neurotrophin-ELP (N-
ELP) fusions, dense water-insoluble aggregates known as inclusion bodies (IBs) are formed. 
Inclusion bodies are partially and misfolded proteins that usually require denaturants like Urea for 
solubilization. Strong denaturants arrest ELPs stimuli-responsive property and increase unwanted 
aggregation, making purification difficult, yet possible. The current field of study exhibit issues 
with protein recovery due to solubility issues and aggregation. This study examines the solubility 
challenges of inclusion body proteins and the role ELP fusion tags play on IBs solubility. Elastin-
like peptides are a class of stimuli-responsive biopolymers whose biocompatibility and limited 
toxicity are attractive for biological applications. ELPs are tunable polymers, which consist of 
peptide repeat units (VPGXG), where X is any amino acid except Proline while the guest residue 
or length of the sequence can be chosen. ELPs have uniquely tunable phase transitioning properties 
that allow the protein to undergo molecular self-assemblies into different nanostructures in 
response to the changes in their environment (e.g. pH or temperature). Optimizing the purification 
process via suppressing aggregation during the refolding process has increased protein recovery 
slightly however, more work is needed to attain 90 percent recovery. Usage of ELPs has increased 
the solubility of N-ELP fusions, specifically for brain-derived neurotrophic factor ELP fusions. 
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CHAPTER 1. INTRODUCTION: CYSTEINE-KNOT GROWTH FACTORS AND 
THEIR IMPLICATIONS IN NEURODEGENERATIVE DISORDERS   
This dissertation reports the investigation of decreasing inclusion body formations of 
cysteine-knot growth factors via the addition of elastin-like polypeptides. Decreasing inclusion 
body formations will allow the production of more soluble proteins per purification cycle. Which 
will decrease the cost of laboratory expenses in time spent, cost of materials, and cost of mental 
and emotional stress of the scientists. Additionally, there is a lack in scientific work in purifying 
cysteine-knot growth factors which are major contributors in neuronal maintenance. 
1.1 Note to Reader  
Part of this chapter was published in Johnson, T., Koria, P., Expression and purification of 
neurotrophin-elastin-like peptide fusion proteins for neural regeneration. BioDrugs, 2016. 30(2): 
pp.117-127. Permission is included in Appendix C. 
1.2 Motivation  
Neural injuries, such as spinal cord injuries, traumatic brain injuries and nerve transection 
injuries pose a major health problem among male adolescents and young adults ages 15 to 24, and 
among people of both sexes 75 years and older. In the United States it is estimated that each year 
approximately 1.4 million people experience traumatic brain injury, costing an estimated $56 
billion dollars. 50,000 of those people will die from head injury. Every year, around the world, 
between 250,000 and 500,000 people suffer a spinal cord injury (SCI). More than a million 
Americans live day-to-day with the disabling effects of SCI. Managing the care of spinal cord 
injury patients approaches $4 billion each year. Despite several advances in neuroscience current 
2 
clinical treatment options for these injuries are severely limited. Due to the limited regenerative 
capacity of the nervous system, treatment options are unable to restore complete function to these 
patients. In the peripheral nervous system, direct end to end surgical reconnection and nerve 
autographs are used to repair the injury gaps in nerves [Trumble and Shon 2000]. However, these 
approaches are limited due to shortage of donor grafts, the potential loss of function at the donor 
sites and the requirement of multiple surgeries. Nerve regeneration in the central nervous system 
is even more challenging; with the inhibitory environment formed after injury in the CNS 
restricting nerve repair [Fawcett and Asher 1999]. There is an increasing demand for identifying a 
treatment that will be less invasive and cost-efficient, that will also increase motor and sensory 
function, as well as elicit axonal regeneration [Blesch and Tuszynski 2009]. These demands have 
been found in cysteine-knot growth factors (CKGFs).  
1.3 Background: Cysteine-Knot Growth Factors  
Growth factors are a group of protein molecules that stimulates a cell’s growth, 
differentiation, and cell-cell communications [Iyer and Acharya 2011, Yuan 2016]. Growth factors 
are generally categorized by their structural and functional similarities. For cysteine-knot growth 
factors, their structure is what ties them together [Iyer and Acharya 2011]. It is unknown whether 
a growth factor is considered a cysteine-knot growth factor (CKGF) until after crystallization [Sun 
and Davies 1995]. The monomers of the cysteine-knot growth factors exhibit three intertwined 
disulfide bridges. Although there are different arrangements of the knot, considering where the 
placement of the cysteine amino acid is, the general structure are two bridges in close proximity 
on adjacent β-strands while the third bridge passes through the two bridges and forms a knot 
(Figure 1.1). These growth factors are a part of a superfamily derived from transforming growth 
factor-beta (TGF-β) [Sun and Davies 1995, Galat 2011, Hinck and Huang 2013]. Phylogenetic 
3 
analysis determines that vascular endothelial growth factor (VEGF), bone morphogenetic protein 
(BMP), platelet-derived growth factor (PDGF), and nerve growth factor (NGF) are members of 
the TGF-β superfamily [Sun and Davies 1995, Galat 2011, Iyer and Acharya 2011]. Currently, the 
aforementioned growth factors are under investigation in The Protein Engineering and Dynamics 
Living Systems Laboratory at the University of South Florida where the work of this dissertation 
was conducted.  
PDGF, epidermal growth factor (EGF), NGF, and other TGF-β superfamily proteins 
stimulate cell growth, survival and differentiation [Alberts 2002, Willerth and Sakiyama-Elbert 
2007, Yuan 2016]. PDGF is a mitogen and can stimulate many types of cells to divide [Alberts 
2002, Yuan 2016]. Mitogens participate in the stimulation of mitosis and assist in cellular 
maintenance [Alberts 2002]. Current research of VEGF, BMP, and PDGF has identified potential 
therapeutic usages in neural regenerative therapy despite the original usages. VEGF has been 
linked to motor neuron disease or amyotrophic lateral sclerosis (ALS) [Oosthuyse et al. 2001, Van 
Den Bosch et al. 2004], Parkinson ’s disease [Wada et al. 2006, Herrán et al. 2013], and 
Alzheimer’s Disease [Chiappelli et al. 2006, Hohman et al. 2015]. BMP has also been linked to 
maintaining the central nervous system [López-Coviella et al. 2000, Wang et al. 2017] by 
improving cognitive function and reducing amyloid plaques [Wang et al. 2017]. PDGF has 
demonstrated its ability to inhibit neuroretinal apoptosis thereby ameliorating photoreceptor 
degeneration [Wang et al. 2014]. Unlike the aforementioned growth factors, NGF was originally 
represented as having immense potential in neural regenerative therapies. NGF is a part of a subset 
family classified as neurotrophins [Levi-Montalcini and Angeletti 1968]. 
 
 
4 
1.3.1 Background: Neurotrophins  
The neurotrophin family share more than 50% of their sequence homology (Figure B.1) 
[Hauburger et al. 2007]. Neurotrophins are a class of neurotrophic factors that will induce neural 
regeneration and axonal differentiation. Neurotrophic factors play a major role in the development, 
neuroprotection, and maintenance of the nervous system. Neurotrophins such as nerve growth 
factor (NGF), neurotrophin-3 (NT-3), brain-derived neurotrophic factor (BDNF) etc. are a family 
of growth factors that play crucial roles in the development and maintenance of the nervous system 
[Willerth and Sakiyama-Elbert 2007]. Consequently, they have been widely investigated for their 
influence on cell mortality, differentiation and function in the CNS and PNS. Neurons not 
receiving appropriate quantities of neurotrophins undergo apoptosis. For signaling, each 
neurotrophin binds to its specific high affinity tyrosine kinase (Trk) receptor with NGF, BDNF 
and NT-3 signaling through the TrkA, TrkB and TrkC receptors respectively [Willerth and 
Sakiyama-Elbert 2007].  
NGF plays critical roles in sympathetic and sensory neuron survival and maintenance 
[Huang and Reichardt 2001], NT-3 plays an important role in neurogenesis [Grill et al. 1997] and 
BDNF helps direct normal neural development and is involved with synaptic transmission and 
maintenance of plasticity [Bramham and Messaoudi 2005]. Additionally, all three possess 
neuroprotective properties which are crucial for nerve repair after injury. Thus they have been 
widely used for treatment of a variety of neural injuries [Mortazavi et al. 2011]. NGF has been 
investigated for treatment of peripheral nerve injuries. NT-3 has been shown to promote survival 
and outgrowth or motor neurons after spinal cord injuries as well as improve peripheral nerve 
regeneration [Willerth and Sakiyama-Elbert 2007]. The potential of BDNF to treat spinal cord 
injuries has also been investigated [Wang et al. 2008].  
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The successful application of neurotrophins in neuronal repair depends on a suitable 
delivery system that ensures the bioavailability of the neurotrophin at the injury site [Willerth and 
Sakiyama-Elbert 2007, Katz and Burdick 2009]. Due to the short in vivo half-life of neurotrophins, 
sustained delivery to the injury site results in significantly better recovery compared to a single 
injection [Katz and Burdick 2009]. Some delivery strategies include the use of scaffolds [Willerth 
and Sakiyama-Elbert 2007], conjugation of the neurotrophins to fibrin gels [Willerth et al. 2007], 
mini-pumps [Sly et al. 2012], hydrogels [Lindsey et al. 2015] or gene therapy [Wolfe et al., 2012]. 
However, strategies requiring chemical conjugation or polymer delivery vehicles still require large 
quantities of growth factor making these therapies prohibitively expensive. On the other hand, 
while gene therapy has proven effective in some cases, several extracellular and intracellular 
barriers must be overcome in order to obtain successful expression of the transgene [Hirsch et al. 
2007]. Moreover, once these barriers have been successfully overcome, there is generally little 
control over the duration of expression or amount of growth factor produced by the transfected 
cell [Byrnes et al. 2001, Yao and Eriksson 2000]. Furthermore, in instances where the delivery of 
multiple growth factors is desired, the recalcitrance of some transfected cells to further 
transfections may be an issue.  
1.4 Elastin-Like Polypeptides  
Elastin-like polypeptides (ELPs) are an attractive drug-delivery application due to their 
ease of production and high-yield expression. ELPs consist of repeats of the VPGXG peptide 
motif, where X can be any amino acid except proline. ELPs are stimuli-responsive biopolymers 
that can be manipulated either by amino acid sequencing or by length to affect their solubility and 
ability to form complex nanostructures, such as scaffolds and nanoparticles. Elastin-like 
polypeptides are capable of fusion proteins which are developed by recombinant DNA technology 
6 
and expressed by isothermal transition cycling (ITC). An interesting property of ELPs is their 
ability to undergo phase transition at physiological temperatures. ELPs are soluble in aqueous 
solutions at a temperature below their lower critical solution temperature (LCST). However, as the 
temperature is raised above their LCST, they undergo an entropically driven contraction rendering 
them insoluble. This property enables recombinant ELPs to be expressed in bacteria and rapidly 
purified to high homogeneity using inverse temperature cycling (ITC) [Meyer and Chilkoti 1999]. 
Moreover, our lab and several others have shown that biologically active moieties, such as growth 
factors, can be fused to ELPs via recombinant DNA technology [Koria et al. 2011, George et al. 
2015, Johnson and Koria 2016, McCarthy et al. 2016]. The fusion proteins retain the biological 
activity of the fused moiety as well as the physical phase transitioning property of ELPs [Koria et 
al. 2011, Johnson and Koria 2016, McCarthy et al. 2016]. Consequently they can be expressed in 
bacteria and purified to high homogeneity using ITC. Additionally, different ELP sequences can 
be chosen or designed so that the fusion protein undergoes molecular self-assemblies resulting in 
the formation of different nano and micro structures when exposed to an external stimulus such as 
changes in temperature or pH. Different structures refer to, but are not limited to, injectable 
hydrogels [Asai et al. 2012], thermoresponsive extracellular matrix [Mie et al. 2008], nanofibers 
[Le et al. 2015], and nanoparticles [Koria et al. 2011, Johnson and Koria 2016, Leonard 2016, 
McCarthy et al. 2016]. ELPs that contain the amino acid cysteine are capable of forming disulfide 
cross-linked hydrogels in-situ [Asai et al. 2012]. These structures are not only useful as scaffolds 
providing the topographical cues for nerve regeneration but they are also useful as drug delivery 
vehicles. 
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1.5 Inclusion Bodies  
ELPs have several attractive features for biological application such as their 
biocompatibility, potential lack of toxicity, and capability of being genetically encodable [Koria 
et al. 2011, Hassouneh et al. 2012]. ELPs can be expressed in prokaryotic hosts, such as 
Escherichia coli (E. coli), which is beneficial because they allow quick and multiple replication of 
the desired gene [Lilie et al. 1998, Singh and Panda 2005, Koria et al. 2011]. However, various 
proteins are overexpressed in prokaryotic hosts because of the rapid rate of protein production. 
This overexpression leads to misfolding of the protein which allows the formation of aggregates 
known as inclusion bodies which are dense water-insoluble aggregates that tend to require strong 
denaturants like 8M urea for solubilization. After denaturation, refolding agents, dilutions, and /or 
dialysis may be needed to refold and purify the denatured protein. Numerous parameters exist to 
produce a bioactive protein, such as temperature, pH, ionic strength, and/or low protein 
concentrations. Producing bioactive proteins after denaturation is a cumbersome process [Rudolph 
and Lilie 1996, Singh and Panda 2005, Singh et al. 2015, Johnson 2016].  
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Figure 1.1 Cysteine Knot Growth Factor. Representation of the disulfide bond knot of 
neurotrophins. The amino acid sequence is written from the N to C terminal and is represented as 
a pink loop. The numbers represent a cysteine (mustard yellow dot) engaged in a disulfide bond. 
The disulfide bonds of the loop are shown in black and the disulfide bond passing through the 
loop, which makes it a knot, is represented as a long black line. Where 1-4 can represent the 
disulfide bonds of Cys15-Cys80 for nerve growth factor and Cys 13-Cys80 for brain-derived 
growth factor, 2-5 can represent Cys58-Cys108 for nerve growth factor and Cys 58-Cys109 for 
brain-derived growth factor, and 3-6 can represent Cys68-Cys110 for nerve growth factor and Cys 
68-Cys111 for brain-derived growth factor. [Acklin et al. 1993, De Young et al. 1996, Rattenholl 
et al. 2001]. 
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CHAPTER 2. CHALLENGES IN PURIFYING INCLUSION BODY PROTEINS   
2.1 Note to Reader  
Part of this chapter was published in Johnson, T., Koria, P., Expression and purification of 
neurotrophin-elastin-like peptide fusion proteins for neural regeneration. BioDrugs, 2016. 30(2): 
pp.117-127. Permission is included in Appendix C. 
2.2 Neurotrophin Folding Mechanisms 
Neurotrophins form dimers when binding to their respective receptors [Philo et al. 1994]; 
because of their dimer conformation, a two-state unfolding process may take place [Eftink 1994]. 
Focusing in on the complexity of NGF’s reversible unfolding and folding mechanisms; De Young 
et al. developed a model demonstrating NGF unfolding and refolding sequentially: N2 to 2M1 to 
2M2, where N represents the native state, M1 represents stage 1 of the unfolding, and M2 is the 
complete unfolding of NGF [De Young et al. 1996, Kliemannel et al. 2006]. Although there is 
agreement on the two-step unfolding process, there is disagreement on why. Rapid unfolding 
happens between the N2 to M1 stage whereas, the slow unfolding occurs between M1 to M2 [De 
Young et al. 1996]. Slow unfolding of pro-NGF may be caused by proline isomerization due to 
the proline’s steric hindrance and their position on the cysteine knot loop [Kliemannel et al. 2006], 
De Young believes the slow unfolding may be due to the loop threading mechanism pro-NGF 
undergoes during unfolding. Whatever the reason for the slow unfolding, certain parameters must 
be kept to allow proper refolding of the neurotrophin. The unfolding and refolding kinetics of NGF 
and other neurotrophins still need further research. Producing recombinant proteins in bacterial 
hosts is simple and cost effective. However, due to the reducing nature of the bacterial cytosol, 
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recombinant proteins that depend on disulfide bonds for stability have difficult times folding 
correctly. Disulfide bonds of cysteine knot growth factors often form incorrect bonds within the 
bacterial cytosol. Since prokaryotic hosts lack the protein’s native chaperones and optimal 
oxidizing environment for CKGFs, the proteins often aggregate during expression and form an 
inclusion body protein (insoluble fraction) [Rattenholl et al. 2001, Cothran et al. 2011, Wingfield 
2015]. However, the oxidizing environment of the periplasm in the bacterial host can support 
disulfide bonding to a minimal which suggests both soluble and insoluble fractions of recombinant 
proteins can be expressed [Wingfield 2015].  
The production of insoluble fractions instead of the desired soluble fractions leads to much 
frustration and intrigue within the scientific community. Previous works have shown that purifying 
misfolded, inclusion body (IB) proteins is arduous and time-consuming. Time is an important 
factor in producing purified recombinant proteins after forming IB proteins because of the 
unfolding and folding mechanisms of the CKGFs. To unfold an IB protein, they are often 
solubilized with a high concentration of denaturant. Urea and Guadinium HCl (GdnHCl) are the 
denaturants commonly used at 8M and 6M, respectively. After which, the unfolded proteins will 
need to be refolded and purified through usage of extensive chromatography and additives. This 
is also a time-dependent process that is currently under review [Rattenholl et al. 2001, Wingfield 
2015, Johnson and Koria 2016]. Various time periods have been used to unfold and denature IB 
proteins with 8M Urea and 6M GdnHCl. Once denatured, the reduced disulfide bonds need to be 
oxidized for renaturation [Song and Sheraga 2000, Vallejo and Rinas 2013]. Prior to oxidation, 
removal of the denaturant should be performed via dialysis or several washes in column 
chromatography. Slow removal of the denaturant will assist in reducing aggregation. Removing 
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the denaturant should be accompanied by additives that assist the protein’s isomerization shuffling 
[Rudolph and Lilie 1996, Pina et al. 2014].  
Isomerization shuffling or intermediate shuffling is the recycling or shuffling process of 
disulfide bonds that occurs during the renaturation/refolding process. The disulfide bonds go 
through a type of “square dance” where the sulfur groups partner with another sulfur group, 
causing unnatural disulfide bridges. These intermediate bonds may cause aggregation if they do 
not shuffle to their original partner during refolding. To circumvent this aggregation, slow 
continuous addition of the solubilized protein can be added to a refolding buffer with continuous 
stirring (dilution). The insolubility of the IB protein, usage of denaturants at high concentrations, 
and aggregation while unfolding and folding all contribute to the low yield of protein produced. 
To inhibit aggregation and increase solubility, additives and expression tags can be used so that 
the denatured protein can refold back to its native state [Rudolph and Lilie 1996, Pina et al. 2014].  
2.3 Increase Solubility  
 Several techniques are used to increase the solubility of recombinant proteins before, 
during, and after expression in order to reduce aggregation or bypass the formation of IBs. The 
following section focuses on increasing solubility before and after expression. 
2.3.1 Reduce Aggregation 
 Aggregation occurs while a protein unfolds and refolds too quickly [Wetlaufer 1995, 
Wingfield 2015]. Reducing aggregation of proteins as they unfold and refold is essential to 
recovering a high yield of bioactive protein. Aggregation during unfolding is difficult to tend to. 
To reduce proteins aggregating during unfolding, solubility fusion tags are used to bypass or 
reduce the formation of IBs. To assist in decreasing aggregation of proteins during refolding, a 
redox system and reducing additives are generally applied. 
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2.3.1.1 Additives  
Additives, such as reduced glutathione (GSH), oxidized glutathione (GSSG), dithiothreitol 
(DTT), L-arginine, and/or ethylenediaminetetraacetic acid (EDTA), are used to reduce protein 
aggregation and to ensure the correct sulfur bond matches with its original partner during 
renaturation [Lyons and Thomason 1995, Rudolph and Lilie 1996]. Disulfide shuffling is also time 
dependent; if left to their own devices, the sulfur bonds can take three days and still not find their 
original partner. This time-dependency invites aggregation formation of a partially bioactive 
protein [Philo et al. 1993, Vallejo and Rinas 2013]. Aggregation occurs because of the misfolded 
monomers with intermediately folded dimers. When GSH and GSSG are added to the shuffling 
process, renaturation takes less time and the disulfide bonds tend to end up with their original 
partner [Lyons and Thomason 1995, Rudolph and Lilie 1996]. Reducing agents like DTT help to 
maintain protein stability by preventing aggregation. However, DTT can be unstable when 
exposed to the air. Using GSH to reduce the disulfide bonds and GSSG to shuffle the bonds may 
be ideal for the refolding buffer. The refolding buffer should have an alkaline pH preferably 
between 8-8.5. Using an alkaline pH is optimal for disulfide bond formation [Rudolph and Lilie 
1996].  
L-arginine is a suppressing agent and has demonstrated promise in suppressing aggregation 
by slowing down the refolding process [Lilie et al. 1998, Wingfield 2015], thereby increasing the 
proteins’ solubility by reducing the potential molecular weight. Usage of L-arginine should be 
limited due to the possible accumulation of reduced cysteines forming intermediate disulfide bonds 
which will lead back to aggregation. Low concentrations of L-arginine as well as a larger redox 
system ratio may allow the proteins to fold correctly to their native state as well as increase the 
yield [Rudolph and Lilie 1996, Schäffner et al. 2001, Tsumoto et al. 2004, Wingfield 2015]. L-
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arginine can also solubilize proteins from IBs; however it may not fully denature inclusion body 
proteins [Tsumoto et al. 2010, Yang et al. 2011].  
EDTA is another additive used to reduce aggregation by removing heavy metals that can 
catalyze oxidative processes and inhibit proteases. EDTA also helps minimize cysteine oxidation 
thereby reducing possible aggregation [Wetlaufer 1995, Wingfield 2015]. 
2.3.1.2 Solubility Fusion Tags 
 Solubility fusion tags may be fused to recombinant proteins to increase the recombinant 
proteins’ solubility and decrease the formation of inclusion body proteins [Wingfield 2015]. 
Solubility fusion tags can be added to the N-terminus or C-terminus of recombinant proteins. 
Fusion tags can be used to detect proteins during purification as well as increase the solubility of 
recombinant proteins during expression. The following sections focuses on three commonly used 
fusion tags. 
2.3.1.2.1 Glutathione-S-Transferase Tag  
Increasing the protein’s solubility is favorable for proteins that are prone to form inclusion 
bodies. Glutathione-S-Transferase (GST) is a fusion tag that enhances the solubility of a protein 
and facilitates the purification of recombinant proteins that were produced in Escherichia coli 
(E.coli). In contrast, high yields of GST fusion proteins may be expressed in E.coli which can 
result in inclusion body proteins, thereby negating the usage of the GST tag as a solubility enhancer 
[Kimple et al. 2013, Pina et al. 2014]. If GST is used in conjunction with a denaturant, the structure 
of the GST fusion tag may degrade [Magdeldin and Moser 2012]; thus using low concentrations 
of denaturants, reducing agents, and non-ionic detergents is suggested for GST tagged fusion 
proteins when they form insoluble aggregates. To purify a protein with the GST fusion tag column 
chromatography is used. Reduced glutathione (GSH) is immobilized to a solid matrix through its 
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sulfhydryl group and can be cross-linked with agarose beads in a column. The protein tagged with 
GST will bind to the immobilized glutathione. A high concentration of free glutathione is used to 
elute the GST tagged protein because GST binds with a higher affinity to free glutathione than 
immobilized GSH [Magdeldin and Moser 2012]. Another benefit to using GST is that it can be 
used in combination with a histidine tag (His-tag) so that the fusion protein can use both the 
specificity of nickel-nitrilotriacetic acid (Ni-NTA) and the solubility enhancement of GST 
[Magdeldin and Moser 2012, Pina et al. 2014]. GST Chromatography depends on the tertiary 
structure of the fusion protein; this dependency is another disadvantage for purifying inclusion 
body proteins [Kimple et al. 2013].  
2.3.1.2.2 FLAG Tag  
A FLAG tag is another promising solubility tag used in purification. A FLAG tag is a 
hydrophilic peptide fused to recombinant proteins to increase solubility. The sequence, 
DYKDDDDK, is made up of one aromatic amino acid with a polar side chain and 7 charged amino 
acids, all containing side chain pKas that are available for hydrogen bonding [Einhauer and 
Jungbauer 2001, Pina et al. 2014]. Multiple FLAG or other solubility tags can be fused to the 
FLAG tag when needed. This property along with the ability to detect the target protein is useful 
for assay-development. However, FLAG tags should not be purified in the presence of denaturants 
because the denaturants may affect the stability of the fusion protein. Due to this dilemma, it is not 
advisable to use FLAG tags in fusion proteins that are prone to forming inclusion bodies [Einhauer 
and Jungbauer 2001].  
2.3.1.2.3 Elastin-Like Polypeptide  
Solubility tags such as elastin-like polypeptides can be used to improve the solubility of a 
protein prone to form inclusion bodies during expression [Christensen et al. 2009, Kowalczyk et 
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al. 2014, George et al. 2015]. Elastin-like polypeptides can be fused to the N-terminus or C-
terminus of recombinant proteins. C-terminus fusions (protein-ELP) tend to be the common 
construct of recombinant protein fusion because of the high yield of protein expressed and 
comparable functional activity to the unfused recombinant protein [Christensen et al. 2009]. The 
flexibility of designing the ELP fusion is an attractive and useful property. ELP tags present a cost 
efficient way to purify recombinant proteins by utilizing the inverse-phase transitioning property 
(Figure B.2) [Ge and Filipe 2006, Christensen et al. 2009, Kowalczyk et al. 2014]. 
Designing an ELP to control the phase transition property may be beneficial to recombinant 
proteins prone to form inclusion body proteins so that the fusion protein will respond favorably to 
stimuli [Ge and Filipe 2006, Christensen et al. 2009, Kowalczyk et al. 2014]. Stimuli such as pH 
or temperature can be used to ensure the ELP fusion is soluble and insoluble at specific times 
throughout the purification process. Another benefit to designing the ELP fusion is its usage in 
regenerative medicine. The ELP phase change property is based on the amino acids present in the 
ELP sequence. Elastin-like polypeptides with hydrophobic or charged amino acids have 
demonstrated mitogenic activity which may be a promising property for eliciting tissue 
regeneration [Yuan 2016]. 
2.3.2 Modifications to Solubilizing Inclusion Body Protein  
 To increase the solubility of IB proteins, low concentrations of urea and GdnHCl may be 
used. Strong denaturants, such as 8M Urea and 6M GdnHCl, increase the possibility of aggregation 
in proteins while unfolding due to the exposure of denatured proteins’ hydrophobic core. 
Maintaining proteins in their native-like secondary structure is ideal so to reduce aggregation, 
increase solubility, and increase the yield of proteins. The following sections will cover two 
alternative denaturation methods for inclusion body proteins. 
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2.3.2.1 Mild Solubilization  
During inclusion body formation, the protein’s native-like secondary structure is 
maintained and reduced [Khan et al. 1998, Qi et al. 2015]. With proteins in their intermediate stage 
and the main culprit of aggregation being the unfolding and refolding process, Panda’s lab suggests 
solubilizing the IB pellet with a mild denaturant [Khan et al. 1998]. Khan et al suggest using 2M 
Urea to denature the IB pellet instead of the commonly used 8M Urea. In strong denaturants, the 
secondary structure is disturbed. Mild solubilization is able to preserve the secondary structure of 
inclusion body proteins, thereby reducing protein aggregation [Panda et al. 2008, Tsumoto et al. 
2010]. Preservation of secondary structures promotes high protein yield recovery [Khan et al. 
1998]. 
Low protein concentration, low denaturant concentration, and a high alkaline pH are 
optimal for protein solubility and recovery [Khan et al. 1998, Patra et al. 2000, Singh et al. 2008]. 
Khan et al. demonstrated that a protein with low concentration, at pH 12 was solubilized without 
usage of a denaturant. Khan et al. also demonstrated that solubilizing the protein at pH 12 resulted 
in the highest protein recovery after refolding via the pulsatile dilution method. Further 
optimization of the mild solubilization method found 2M Urea Tris buffers at pH 12.5 to be less 
susceptible to aggregation [Patra et al. 2000]. Increasing the denaturant concentration from 2M to 
8M does not drastically increase the solubility of the inclusion body protein. With comparable 
soluble protein and with the increasing of denaturant molar concentration, the mild solubilization 
technique may be useful in reducing aggregation and increasing protein yield [Khan et al. 1998].  
2.3.2.2 Freeze-Thaw Method  
The freeze thaw method selectively releases recombinant protein from the bacterial cellular 
components at high purity and yield. Repeated freezing and thawing damages cellular membrane, 
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thereby degrading the bacterial cellular membrane and releasing the recombinant proteins. 
However proteins with concentrations over 29kDa generally produce low yields. Another 
disadvantage is that inclusion body proteins do not secrete in this method [Johnson and Hecht 
1994]. To utilize this method and solubilize inclusion body proteins, mild solubilization with 2M 
Urea is used in conjunction with freezing and thawing the inclusion body pellet.  
Freeze-thaw and mild solubilization promote denaturation of a protein by destabilizing the 
tertiary structure while still maintaining its secondary structure. When compared to the traditional 
8M Urea denaturation, the freeze-thawing/mild solubilization method has produced approximately 
double the soluble protein [Qi et al. 2015]. By not using a strong denaturant, the freeze thaw 
method may in fact reduce the possibility of aggregation throughout the purification process [Singh 
et al. 2015], thereby increasing solubility along with the protein yield. 
2.4 Optimizing Protocol  
 Several purification trials were performed to increase the solubility and protein yield of the 
N-ELPs while attempting to reduce the aggregation of the N-ELPs during unfolding and refolding. 
Additives and time were used to determine if there would be an increase in yield or purity of the 
N-ELP fusion proteins. An increase in yield or purity would demonstrate an increase in solubility 
and a decrease in aggregation. 
2.4.1 Materials and Methods 
 Each section will discuss the various materials, i.e. plasmids, salts, detergents, denaturants, 
and additives that were used at each step and in each purification trial. 
2.4.1.1 Synthesis of Genes Encoding Neurotrophin-ELP Fusion Proteins  
For this study, the PUC57 plasmid containing the gene encoding recombinant human NGF 
(UniProtKB-P01138, Ser122-Ala241) and recombinant human BDNF (UniProtKB-P23560, 
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His129-Arg247) were purchased from GenScript. The PUC19 plasmid containing the elastin 
cassette V40C2, (VPGVG)40(VPGVGVPGVGVPGCGVPGVGVPGVG)2, has been described 
previously [Koria et al. 2011]. The PUC19 plasmid containing the elastin cassette V40C4, 
(VPGVG)40(VPGVGVPGVGVPGCGVPGVGVPGVG)4 was developed by adding two cassettes 
of VPGVGVPGVGVPGCGVPGVGVPGVG to the V40C2 elastin cassette via recursive 
directional ligation. PflMI and BglI enzymes were used to excise the gene fragment encoding 
recombinant NGF or BDNF from the PUC57 plasmid. The excised gene fragments were cloned in 
frame in the plasmid containing the elastin cassette to create a gene encoding either NGF-V40C4, 
NGF-V40C2 or BDNF-V40C2 as described previously [Meyer and Chilkoti 2002, Koria et al. 
2011]. The gene encoding the fusion proteins was then excised from the PUC19 plasmid and 
inserted into the expression plasmid pET25b+ for protein expression.  
2.4.1.2 Expression of Neurotrophin-ELPs  
The expression vector pET25b+ containing NGF-V40C4, NGF-V40C2 or BDNF-V40C2 
was transformed into E.coli BLR (DE3) cells through heat shock at 42◦C. A starter culture of 75mL 
was then inoculated overnight and added to a 1L culture the next day. The 1L culture was then 
propagated overnight. The next day, bacterial cells were harvested by centrifugation (3000g, 20 
minutes) at 4◦C. Proteins were expressed as insoluble (IB protein) and soluble proteins. 
2.4.1.3 Solubilization and Refolding Trials of Neurotrophin-ELPs  
Previous trials discovered NGF-ELP formed IB pellets and was not soluble in PBS. 
Denaturants were tested on the NGF-V40C4 IB Pellet and 8M Urea, and 1X Tris was found to be 
sufficient for solubilizing the IB Pellet (Figure 2.1). 
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2.4.1.3.1 Solubilization and Production of Lyophilized NGF-V40C4 
The bacterial cells were re-suspended in 1X PBS and lysed by sonic disruption on ice (6 
cycles, 50% amplitude, and 59 seconds on/off). The solution was centrifuged at 4◦C (20,000g, 15 
minutes) and the pellet containing the inclusion body protein was collected while the supernatant 
was discarded. The spun down bacterial pellet was re-suspended and solubilized in 100mL of 8M 
Urea (Figure 2.2: Lane 1, 2) and centrifuged at 4◦C (15,000g, 20 minutes). The denatured pellet 
was re-suspended in DI water and kept for western blot testing (Figure 2.2: Lane 3, 4). A previous 
experiment was done to show that ELP’s will not transition at 42◦C unless 8M Urea is removed. 
The lack of phase transitioning in 8M Urea suggest that the ELP’s phase transition property was 
arrested or the ELP fusion property’s transition temperature had increased. The supernatant was 
dialyzed against DI water overnight at 4◦C (Figure 2.2: Lane 5). Precipitation occurred; however, 
the purification process continued. The next day, 1M NaCl was added to the supernatant and placed 
into the water bath at 42◦C for 30 minutes. After the water bath, a sample of the mixture was taken 
for western blot analysis (Figure 2.2: Lane 6). The mixture was then centrifuged at 40◦C (10,000g, 
15 minutes). A sample of the hot supernatant was taken for western blot analysis (Figure 2.2: Lane 
7). The pellet was re-suspended in 50 mL DI water and centrifuged at 4◦C (15,000g, 20 minutes). 
The solution was dialyzed for 2 days against DI water to remove salts. After dialysis, a sample 
was taken for analysis (Figure 2.2: Lane 8). The supernatant was frozen at -80C for 1 hour and 
then lyophilized. The lyophilized sample was re-suspended in cold 1X PBS and a sample was 
taken for analysis (Figure 2.2: Lane 9). 
2.4.1.3.2 Lysis Buffer Assists in the Solubilization of NGFV40C4 
The bacterial cells were re-suspended in 160mL of lysis buffer (50mM Tris Base, 10% 
Glycerol, 0.1% Triton X-100, 1mM EDTA, 100ug/mL Lysozyme, pH 7.4) and lysed by sonic 
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disruption on ice (6 cycles, 50% amplitude, and 59 seconds on/off). The solution was centrifuged 
at 4◦C (20,000g, 15 minutes) and the pellet containing the inclusion body protein was collected 
while the supernatant (supn) was kept for analysis (Figure 2.3: Lane 1). The spun down bacterial 
pellet (Figure 2.3: Lane 2) was re-suspended and solubilized in 100mL of solubilizing buffer (8M 
Urea, 10mM DTT, pH 8) and centrifuged at 4◦C (15,000g, 20 minutes). A sample of the 
supernatant was taken prior to dialysis against DI water overnight at 4◦C (Figure 2.3: Lane 3). The 
next day, precipitation occurred again and a sample of the supernatant was taken after dialysis 
(Figure 2.3: Lane 4). Then, 1M NaCl was added to the supernatant and placed into the water bath 
at 42◦C for 30 minutes. After the water bath, the mixture was then centrifuged at 40◦C (10,000g, 
15 minutes). A sample of the hot supernatant was taken for western blot analysis (Figure 2.3: Lane 
5). The hot pellet was kept and re-suspended in a transition buffer (2M Urea, 10mM DTT). The 
cold supernatant (Figure 2.3: Lane 7) was kept for protein purification and the cold pellet was re-
suspended in 2M Urea for western blot analysis (Figure 2.3: Lane 6). 1M NaCl was added to the 
cold supernatant and a hot spin was done at 40◦C (10,000g, 15 minutes). A sample of the hot 
supernatant was taken for western blot analysis (Figure 2.3: Lane 8). The pellet was tiny so the hot 
supernatant was spun again at 40◦C (10,000g, 15 minutes). A sample of the hot supernatant was 
kept (Figure 2.3: Lane 9). The pellet was re-suspended in 100 mL of a transition buffer (2M Urea, 
10mM DTT) and centrifuged at 4◦C (15,000g, 20 minutes). The cold supernatant (Figure 2.3: Lane 
11) was kept for protein purification and the cold pellet was re-suspended in 2M Urea for western 
blot analysis (Figure 2.3: Lane 10). 1M NaCl was added to the cold supernatant and a hot and cold 
spin was performed again. The hot pellet is re-suspended in 50mL DI water and then spun down 
at 4◦C (15,000g, 20 minutes). Samples of the hot supernatant (Figure 2.3: Lane 12), cold pellet 
(Figure 2.3: Lane 13), and a cold supernatant (Figure 2.3: Lane 14) were kept for analysis. The 
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cold supernatant was dialyzed for 2.5 days against DI water to remove salts. The supernatant was 
frozen at -80◦C for 1 hour and then lyophilized. 
2.4.1.3.3 Refolding NGF-V40C2 
Two protocols were used in this section; one concerning refolding NGF-V40C2 for 32 
hours and another for 17 hours. Both protocols were conducted similarly. The bacterial cells were 
vortexed to resuspend in 25mL 1X Tris washing buffer (50mM Tris Base, 10% Glycerol, 1% 
Triton X-100, 1mM EDTA, 50mM DTT, pH 7.4), sonicated by sonic disruption on ice (6 cycles, 
50% amplitude, and 59 seconds on/off), then centrifuged at 4◦C (20,000g, 15 minutes) and a sample 
was collected of the supn then discarded. The pellet was vortexed to resuspend again in the 
washing buffer, sonicated again, then centrifuged at 4◦C (20,000g, 15 minutes) once more, supn 
sample collected then discarded. The pellet was vortexed to resuspend in lysis buffer (50mM Tris 
Base, 10% Glycerol, 1% Triton X-100, 1mM EDTA, 50mM DTT, 100ug/mL Lysozyme, 100mM 
NaCl, pH 7.4) and lysed by sonic disruption on ice (6 cycles, 50% amplitude, and 59 seconds 
on/off). The solution was centrifuged at 4◦C (20,000g, 15 minutes) and the pellet containing the 
inclusion body protein was collected while the supernatant was kept for analysis. The spun down 
bacterial pellet was vortexed and solubilized in 100mL of solubilizing buffer (8M Urea, 10mM 
DTT, pH 8). The mixture was then sonicated and centrifuged at 4◦C (15,000g, 20 minutes). The 
pellet was resuspended in 1X Tris Buffer for western blot analysis. A sample of the supernatant 
was taken prior to step-wise dialysis against 6M to 4M to 2M overnight at 4◦C. The next day, there 
was no precipitation. 1M NaCl was added to the supernatant and placed into the water bath at 42◦C 
for 30 minutes. After the water bath, the mixture was then centrifuged at 40◦C (10,000g, 15 
minutes) twice. A sample of the hot supernatant was taken for western blot analysis. The hot pellet 
was kept and resuspended in 100mL of a transition buffer (2M Urea, 10mM DTT, pH 9.5). The 
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cold supernatant was kept for protein purification and the cold pellet was vortexed and resuspended 
in 2M Urea for western blot analysis. 1M NaCl was added to the cold supernatant and a hot spin 
was done at 40◦C (10,000g, 15 minutes) twice. A sample of the hot supernatant was taken for 
western blot analysis. The pellet was resuspended in 100 mL of a transition buffer (2M Urea, 
10mM DTT, pH 9.5) and centrifuged at 4◦C (15,000g, 20 minutes). The cold supernatant was kept 
for protein purification and the cold pellet was re-suspended in 2M Urea for western blot analysis. 
1M NaCl was added to the cold supernatant and a hot and cold spin was performed again. The hot 
pellet was resuspended in 50mL of the transition buffer and then spun down at 4◦C (15,000g, 20 
minutes). Samples of the hot supernatant, cold pellet, and a cold supernatant were kept for analysis. 
Refolding additives were added to the 3rd spin cold supn for refolding for 32 hours: 5mM EDTA, 
5mM reduced glutathione (GSH) added first for an hour at room temperature (Rt), then 1M L-
arginine added for 15 minutes at Rt, then 1mM oxidized glutathione (GSSG) for the remainder of 
time at 4◦C. Sample was taken (Figure 2.4A: Lane 13). Crystals formed: mixture centrifuged and 
supernatant decanted for dialysis. The cold supernatant was dialyzed for 2.5 days against DI water 
to remove salts. The supernatant was frozen at -80◦C for 1 hour and then lyophilized. 
Here are the changes made to the second protocol: resuspension in 50mL 8M Urea then 
cold spin and repeat resuspension and spin instead of sonication in 100mL 8M Urea, decreased 
arginine concentration 400Mm and refolding time 17 hours (Figure 2.4B). No crystals formed. 
Faint dimer formation. 
2.4.1.3.4 Decreasing Protein Lost in Hot Supernatant 
There were three different protocols being conducted simultaneously: “Battle of the 
Protocols”. In which there was a Refolding Protocol, Long Haul Protocol, as well as the Original 
Protocol. All three protocols began similarly. The bacterial cells were vortexed to resuspend in 
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25mL 1X Tris washing buffer (50mM Tris Base, 10% Glycerol, 1% Triton X-100, 1mM EDTA, 
50mM DTT, pH 7.4), sonicated by sonic disruption on ice (6 cycles, 50% amplitude, and 59 
seconds on/off), then centrifuged at 4◦C (20,000g, 15 minutes) the supn was discarded. The pellet 
was vortexed to resuspend again in the washing buffer, sonicated again, then centrifuged at 4◦C 
(20,000g, 15 minutes) once more, supn was discarded. The pellet was vortexed to resuspend in 
lysis buffer (50mM Tris Base, 10% Glycerol, 1% Triton X-100, 1mM EDTA, 50mM DTT, 
100ug/mL Lysozyme, 100mM NaCl, pH 7.4) and lysed by sonic disruption on ice (6 cycles, 50% 
amplitude, and 59 seconds on/off). The solution was centrifuged at 4◦C (20,000g, 15 minutes) and 
the pellet containing the inclusion body protein was collected while the supernatant was kept for 
analysis. The spun down bacterial pellet was vortexed and solubilized in 50mL of solubilizing 
buffer (8M Urea, 10mM DTT, pH 8). The supernatant was kept on ice and the pellet was vortexed 
to resuspend into 50mL of an acidic solubilizing buffer (8M Urea, 10mM DTT, pH 3). A sample 
of the supernatant was taken prior to step-wise dialysis against 6M to 4M to 2M overnight at 4◦C. 
The Refolding Protocol consisted of 200mL. Prior to the supernatant being dialyzed, 
refolding additives were added to the supernatant for refolding for 72 hours: 5mM EDTA, 5mM 
GSH added first for an hour, then 1M L-arginine added for 15 minutes, then 1mM GSSG for 
remainder of time (Figure 2.5: Lane 2). After dialysis (Figure 2.5: Lane 3), 1M NaCl was added 
to the refolded supernatant and placed in the water bath for 30 minutes. Afterwards, a hot spin was 
conducted. The hot pellet was resuspended in cold 1X PBS, (10mM DTT, pH 7.4). A cold spin 
was performed and the insoluble contaminants were separated from the soluble protein. The cold 
supernatant was kept and 1M NaCl was added to the supernatant and placed into the water bath at 
42◦C for 30 minutes. After the water bath, the mixture was then centrifuged at 40◦C (10,000g, 15 
minutes). The hot pellet was kept and resuspended in 100mL of a transition buffer (2M Urea, 
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10mM DTT, pH 9.5). This cycle was repeated and on the third cycle the hot pellet was resuspended 
in 50mL transition buffer (2M Urea, 10mM DTT, pH 9.5). The cold supernatant was dialyzed for 
2.5 days against DI water to remove salts. The supernatant was frozen at -80◦C for 1 hour and then 
lyophilized. 
800mL was used for the “Long Haul” protocol. There was no precipitation the next day 
after dialysis done at room temperature. 1M NaCl was added to the supernatant and placed into 
the water bath at 42◦C for 30 minutes. After the water bath, the mixture was then centrifuged at 
40◦C (10,000g, 15 minutes). The hot pellet was kept and resuspended in 100mL of a transition 
buffer (2M Urea, 10mM DTT, pH 9.5). The protein was incubated at 25◦C for 51 hours (Figure 
2.5, Lane 10). The mixture was placed on ice for 1 hour and then centrifuged at 4◦C (15,000g, 20 
minutes). The cold supernatant was kept for protein purification and 1M NaCl was added to the 
cold supernatant and placed in the water bath for 30 minutes. Hot and cold spins were performed 
again for two more cycles. On the third cycle, the hot pellet was resuspended in 50mL of the 
transition buffer and then spun down at 4◦C (15,000g, 20 minutes). The cold supernatant was 
dialyzed for 2.5 days against DI water to remove salts. The supernatant was frozen at -80◦C for 1 
hour and then lyophilized. 
A one liter batch of protein was used for the “Original” protocol. The next day, after 
dialysis, 1M NaCl was added to the supernatant and placed into the water bath at 42◦C for 30 
minutes. After the water bath, the mixture was then centrifuged at 40◦C (10,000g, 15 minutes). The 
hot pellet was kept and resuspended in 100mL of a transition buffer (2M Urea, 10mM DTT, pH 
9.5). The mixture was then centrifuged at 4◦C (15,000g, 20 minutes). The cold supernatant was 
kept for protein purification and 1M NaCl was added to the cold supernatant and placed in the 
water bath for 30 minutes. Hot and cold spins were performed again for two more cycles. On the 
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third cycle, the hot pellet is resuspended in 50mL of the transition buffer and then spun down at 
4◦C (15,000g, 20 minutes). The cold supernatant was dialyzed for 2.5 days against DI water to 
remove salts. The supernatant was frozen at -80◦C for 1 hour and then lyophilized. The lyophilized 
protein was resuspended in 1X PBS for testing (Figure 2.5: Lane 7). 
2.4.1.3.5 Strong Ionic Interactions Increased Protein Solubility without Refolding Additives 
The bacterial cells were vortexed to resuspend in 25mL 1X Tris washing buffer (50mM 
Tris Base, 10% Glycerol, 1% Triton X-100, 1mM EDTA, 50mM DTT, pH 7.4), sonicated by sonic 
disruption on ice (6 cycles, 50% amplitude, and 59 seconds on/off), then centrifuged at 4◦C 
(20,000g, 15 minutes) the supn was discarded. The pellet was vortexed to resuspend again in the 
washing buffer, sonicated again, then centrifuged at 4◦C (20,000g, 15 minutes) once more, supn 
was discarded. The pellet was vortexed to resuspend in lysis buffer (50mM Tris Base, 10% 
Glycerol, 1% Triton X-100, 1mM EDTA, 50mM DTT, 100ug/mL Lysozyme, 100mM NaCl, pH 
7.4) and lysed by sonic disruption on ice (6 cycles, 50% amplitude, and 59 seconds on/off). The 
solution was centrifuged at 4◦C (20,000g, 15 minutes) and the pellet containing the inclusion body 
protein was collected while the supernatant was kept for analysis. The spun down bacterial pellet 
was vortexed and solubilized in 50mL of solubilizing buffer (8M Urea, 10mM DTT, pH 8) (Figure 
2.6: Lane 1). The supernatant was kept on ice and the pellet was vortexed to resuspend into 50mL 
of an acidic solubilizing buffer (8M Urea, 10mM DTT, pH 3) (Figure 2.6: Lane 2). A sample of 
the supernatant was taken prior to step-wise dialysis against 6M to 4M to 2M overnight at 4◦C. 
Protein was salted out with 1M ammonium sulfate and placed in the water bath. Hot centrifuge, 
kept pellet. Resuspended pellet in transition buffer (2M Urea, 10mM, pH 9.5). Cold spin, kept 
supernatant, discarded pellet. Second cycle with 1M (NH4)2SO4. Repeated hot and cold spin. Third 
cycle, protein was salted out with ammonium chloride. On the third cycle, the hot pellet was 
30 
resuspended in 50mL of the transition buffer and then spun down at 4◦C (15,000g, 20 minutes). 
The cold supernatant was dialyzed for 2.5 days against DI water to remove salts. The supernatant 
was frozen at -80◦C for 1 hour and then lyophilized. 
2.4.1.3.6 Dimer Formation of BDNF-V40C2 without Refolding Additives 
This section contains two very similar protocols for purifying BDNF-V40C2. The spun 
down bacterial pellet was vortexed and solubilized in 160mL in 1X PBS), then centrifuged at 4◦C 
(20,000g, 15 minutes); the supn was kept for western blot analysis Figure 2.7A:.Lane 1) The pellet 
was vortexed to resuspend in 25mL 1X Tris washing buffer (50mM Tris Base, 10% Glycerol, 1% 
Triton X-100, 1mM EDTA, 50mM DTT, pH 7.4), sonicated by sonic disruption on ice (6 cycles, 
50% amplitude, and 59 seconds on/off), then centrifuged at 4◦C (20,000g, 15 minutes) the supn 
was discarded. The pellet was vortexed to resuspend in lysis buffer (50mM Tris Base, 10% 
Glycerol, 1% Triton X-100, 1mM EDTA, 50mM DTT, 100ug/mL Lysozyme, 100mM NaCl, pH 
7.4) and lysed by sonic disruption on ice (6 cycles, 50% amplitude, and 59 seconds on/off). The 
solution was centrifuged at 4◦C (20,000g, 15 minutes) and the pellet containing the inclusion body 
protein was resuspended in 50mL of solubilizing buffer (8M Urea, 100mM DTT, pH 8) while the 
supernatant was kept for analysis (Figure 2.7A: Lane 2). The supernatant was kept on ice and the 
pellet was vortexed to resuspend into 50mL of an acidic solubilizing buffer (8M Urea, 10mM DTT, 
pH 3). A sample of the supernatant (Figure 2.7A: Lane 3) was taken prior to step-wise dialysis 
against 6M to 4M to 2M overnight at 4◦C. Protein was salted out with 1M ammonium chloride 
(NH4Cl) and placed in the water bath. Hot centrifuged, kept pellet. Resuspended pellet in transition 
buffer (2M Urea, 10mM, pH 9.5). Cold spin, keep supernatant, discard pellet. Second cycle with 
1M NH4Cl. Repeated hot and cold spin. Third cycle, protein was salted out with ammonium 
chloride. On the third cycle, the hot pellet was resuspended in 50mL of the transition buffer and 
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then spun down at 4◦C (15,000g, 20 minutes). The cold supernatant was dialyzed for 2.5 days 
against DI water to remove salts. The supernatant was frozen at -80◦C for 1 hour and then 
lyophilized. 
The spun down bacterial pellet was vortexed and solubilized in 25mL in 1X Tris washing 
buffer (50mM Tris Base, 10% Glycerol, 1% Triton X-100, 1mM EDTA, 50mM DTT, pH 7.4), 
then centrifuged at 4◦C (20,000g, 15 minutes); the supn was kept for western blot analysis (Figure 
2.7B: Lane 1). The pellet was vortexed to resuspend again in 25mL 1X Tris washing buffer (50mM 
Tris Base, 10% Glycerol, 1% Triton X-100, 1mM EDTA, 50mM DTT, pH 7.4), then centrifuged 
at 4◦C (20,000g, 15 minutes) the supn was discarded. The pellet was vortexed to resuspend in lysis 
buffer (50mM Tris Base, 10% Glycerol, 1% Triton X-100, 1mM EDTA, 50mM DTT, 100ug/mL 
Lysozyme, 100mM NaCl, pH 7.4) and lysed by sonic disruption on ice (6 cycles, 50% amplitude, 
and 59 seconds on/off). The solution was centrifuged at 4◦C (20,000g, 15 minutes) and the pellet 
containing the inclusion body protein was resuspended in 50mL of solubilizing buffer (8M Urea, 
100mM DTT, pH 8) while the supernatant was kept for analysis. The supernatant was kept on ice 
and the pellet was vortexed to resuspend into 50mL of an acidic solubilizing buffer (8M Urea, 
10mM DTT, pH 3). A sample of the supernatant was taken prior to step-wise dialysis against 6M 
to 4M to 2M overnight at 4◦C. Protein was salted out with 1M ammonium chloride (NH4Cl) and 
placed in the water bath for 30 minutes. Hot centrifuged, kept pellet. Resuspended pellet in 
transition buffer (2M Urea, 10mM, pH 9.5) and underwent sonic disruption on ice (3 cycles, 50% 
amplitude, and 30 seconds on/off). Cold spin, kept supernatant, discard pellet. Second cycle with 
1M NH4Cl. Repeated hot and cold spin including sonication of the hot pellet in the transition 
buffer. Third cycle, protein was salted out with ammonium chloride. On the third cycle, the hot 
pellet was resuspended in 50mL of the transition buffer and then spun down at 4◦C (15,000g, 20 
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minutes). Cold spin conducted to remove further impurities. A fourth cycle was conducted. The 
protein was salted out with ammonium chloride. On this last cycle, the hot pellet was resuspended 
in 50mL of the transition buffer and then spun down at 4◦C (15,000g, 20 minutes) (Figure 2.7B: 
Lane 6). The cold supernatant was dialyzed for 2.5 days against DI water to remove salts. The 
supernatant was frozen at -80◦C for 1 hour and then lyophilized. 
2.4.1.4 Trial Assessments while Optimizing Protocol  
The solubility of recombinant proteins were analyzed by electrophoresis on a 15% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. 
Western-blotting was performed with NGF antibody (Cell Signaling, 1:1000) or BDNF antibody 
(R&D Systems, 1:100).  
2.4.2 Results  
Here, we report the expression and purification of NGF-V40C4, NGF-V40C2 and BDNF-
V40C2 labeled as NGF-ELP and BDNF-ELP. The fusion proteins were expressed in bacteria as 
soluble and insoluble proteins (inclusion body proteins). Both fusion proteins were purified 
successfully to high homogeneity from inclusion bodies using inverse temperature cycling (ITC) 
and urea. Preliminary results suggested usage of a wash buffer, lysis buffer, solution buffer (8M 
Urea, 10mM DTT, 1X Tris, pH 8), transition buffer (2M Urea, 10mM DTT, 1X Tris, pH 12.5), 
and refolding buffer (5:1 GSH-GSSG, Arginine).  
2.4.2.1 Neurotrophin-ELP Fusion Proteins are Expressed in Bacteria as Inclusion Bodies  
The gene encoding recombinant NGF was cloned at the N-terminus of the ELP variant 
(VPGVG)40(VPGVGVPGVGVPGCGVPGVGVPGVG)4 to create a gene encoding protein of 
NGF-V40C4. The genes encoding recombinant NGF and BDNF were cloned at the N-terminus of 
the ELP variant (VPGVG)40(VPGVGVPGVGVPGCGVPGVGVPGVG)2 to create two genes 
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encoding proteins of the form NGF-V40C2 and BDNF-V40C2. The three genes encoding the 
fusion proteins were cloned into the modified pET25b+ expression plasmid for protein expression 
in bacterial cells (BLR strain). Western blots using antibody specific to the neurotrophins 
demonstrated the successful expression of the proteins in bacterial cells. Interestingly, these fusion 
proteins were expressed as inclusion bodies (Figure 2.2 and 2.7). 8M Urea in 1X Tris was 
determined to be the more effective denaturing buffer in the allotted time (Figure 2.1). 
2.4.2.2 Activating Phase Transition Property of ELP Fusion Protein by Removing 8M Urea 
NGF-V40C4 was expressed as an inclusion body protein and was denatured with 8M Urea. 
The presence of soluble protein in the IB protein pellet after denaturation was unexpected; 
especially soluble protein soluble by DI water. The IB pellet may have still contained traces of 8M 
Urea and 1X Tris, so adding the DI water for testing may not have been a true representation of 
DI water’s ability to solubilize the denatured pellet. After sonication and denaturation some soluble 
protein was released from the IBs; after which, the soluble protein was exposed to interactions of 
the present contaminants and aggregated protein. Soluble protein may have interacted with the 
insoluble aggregates and was pelleted during centrifugation. Solubilizing in DI water after 
denaturation offers a chance to solubilize the proteins and limit aggregation. 
A previous ITC run discovered that unless 8M Urea was removed from the denatured 
protein the phase transition property of the ELP fusion was not activated. Thus, ITC was not 
effective without the removal of 8M Urea. Once the strong denaturant was removed by dialysis, 
the phase transition property of the ELP fusion was retained. Hot and cold spins were conducted 
and despite the need for denaturing, the hot pellets (which contain the protein) were soluble in DI 
water. Also, there was not much protein loss in the hot supernatants. Once purified, NGF-V40C4 
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was lyophilized and resuspended in PBS. Lyophilized protein was difficult to dissolve and partially 
soluble in PBS afterwards. 
Lysed supernatant was used to assist in removing bacterial contaminants from the IBs. 
Minimal loss is expected per cycles however, there was a substantial loss of protein loss in the 
cold pellets and hot supernatants (Figure 2.3). Monomers and dimers aggregated with the insoluble 
proteins and were pelleted out during the cold spins. ELP fusion proteins should be in the cold 
supernatant however, aggregation is occurring despite the usage of 2M Urea to keep the protein in 
its reduced state. Due to the presence of 2M Urea, a longer incubation may be needed to increase 
the salting out potential of the N-ELP fusion proteins and decrease their presence in the hot 
supernatant. No additives were used which may have contributed to the aggregation of 
NGFV40C4. 
2.4.2.3 Produced Dimers and Increased Protein Solubility of N-ELPs after Denaturation 
Soluble and insoluble proteins were expressed (Figure 2.4). Soluble proteins were soluble 
in the wash and lysis buffers. The increase in solubility may be due to the 10 fold increase of Triton 
X-100 in the wash and lysis buffers. Usage of glycerol is also beneficial to solubilizing proteins 
and bacterial contaminants. Increased viscosity may prevent aggregation and precipitation and 
may have allowed the proteins to interact with glycerol like water. Triton X-100 stabilizes the 
precipitation effect in glycerol and increases the solubility of proteins. Triton X-100 is protein 
dependent and was used to increase the protein solubility by removing contaminants [Shiamoto 
1998]. Unfortunately it may have assisted in the decrease of the protein yield by removing soluble 
proteins from the insoluble aggregates. Additionally, sonication contributed to the release of 
soluble proteins from the insoluble aggregates.  
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According to Dr. Rudolph, the solubilization time is not enough time for the IBs to be 
solubilized and denatured. The lack of complete denaturation may be why dimer formations are 
still present after 8M Urea denaturation. Despite the usage of DTT in the 2M Urea, there is still 
substantial loss of protein in the cold pellet (Figure 2.4B: Lane 6, 7, 9). Aggregation is still seen 
throughout the purification process. Aggregation of NGF-V40C2 appeared to be decreased after 
refolding however, once the additives were removed NGF-V40C2 formed trimers (Figure 2.4A: 
Lane 13) which suggests aggregation of the dimers with free monomers.  
The refolding buffer used was modeled after Dr. Rainer Rudolph’s and Dr. Panda’s 
refolding buffers. Although pH at 12 and 12.5 was optimal for Dr. Panda’s research, Dr. Rudolph’s 
lab has suggested a pH of 9.5 for pro-NGF which is why the pH of the transition buffer was at 9.5. 
In both refolding processes dimerization is seen however, the refolding buffer that was incubated 
at a longer interval exhibited the most pronounce dimer seen from all trials conducted. Refolding 
of NGF is stated to go through disulfide isomerization and take up to 3 days to complete which 
may be why dimer formation appears to be more pronounced in Figure 2.4A than in Figure 2.4B, 
based on the 32 hours of refolding versus the 17 hours of refolding respectively. 
“Battle of Protocols” shows the importance of room temp solubilization and dialysis; also 
strong salt reduces loss of protein and increased the protein yield (Figure 2.5). Despite the 
knowledge, substantial amount of protein is being loss in the cold pellets still. The Refold protocol 
attempted to reduce aggregation of the protein by attempting to refold NGFV40C2 prior to 
purification. Keep in mind refolding additives were added to 8M Urea which we know seriously 
alters proteins’ abilities to be functional. However, after 72 hours, the protein should be completely 
solubilized which would mean aggregation should be reduced. Subsequently, 8M Urea was 
removed so the ELP phase transition property could be utilized. Removal of 8M Urea was 
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performed by dialysis at room temperature; no precipitation of the protein was formed. 
Aggregation was reduced during dialysis however, after the protein is salted out loss of protein is 
seen throughout the ITC process, loss of protein was seen in the cold pellets and hot supernatants. 
It should be thought that with each cycle unfolding and refolding are continuously occurring. 
Reducing the cycles will be beneficial and reduce protein loss. 
In the Long Haul protocol, the first hot pellet (insoluble protein) was allowed to be 
resuspended and incubated at Rt for an extensive period of time, which enhanced protein recovery 
and reduced aggregation in the 1st cold pellet. Unfortunately incubating the protein on ice for 1 
hour prior to the cold spin may have increased aggregation of the protein. Cold spins are done in 
2M Urea; urea needs more energy to solubilize proteins. There is less energy available for urea at 
colder temperatures which may be the main reason there is so much aggregation in the cold pellets. 
Additionally, the Long Haul protocol produced the highest yield of protein however, there were 
immense solubility issues once lyophilized. The lyophilized protein was difficult to solubilize in 
1X PBS. Stock solutions of the Long Haul protocol were solubilized in 2M Urea and then dialyzed 
and filtered for characterization and bioactivity studies. All lyophilized proteins formed dimers no 
matter which protocol was used. 
Strong salts such as ammonium sulfate and ammonium chloride were used to salt out the 
target protein (Figure 2.6). Strong ionic interactions increased the salting out of the N-ELP fusions 
thereby reducing the protein loss in the hot supernatants however, loss in the cold pellets are still 
seen. Loss of protein was even seen after ITC cycles suggesting that even with the removal of urea 
the N-ELP fusion protein will still aggregate at 4◦C. It is quite possible that if 2M Urea was not 
used as a transition buffer during the purification process, there would be a greater loss of protein 
due to aggregation at 4◦C. This continued aggregation at lower temperatures may be due to the 
37 
presence of free monomers aggregating with partially folded proteins. Reducing the presence of 
free monomers and increasing the presence of dimers may circumvent the aggregation at lower 
temperatures. 
The usage of washing buffers and sonication were altered for purifying BDNF-V40C2 
(Figure 2.7). PBS was used to wash the protein but it was discovered that BDNF-V40C2 was 
soluble in PBS. However, there was still protein that was insoluble in PBS. This is further evidence 
that N-ELPs form both soluble and insoluble proteins during expression. Purification of the soluble 
proteins expressed for N-ELPs may be an easier purification process because there would be no 
need for denaturants. 
Since sonication contributes to releasing soluble proteins and it is possible for soluble 
protein to be intertwined with inclusion body protein, sonication was not done with each wash 
(Figure 2.7B) Sonication was done with each hot pellet resuspension so to release more protein 
along with the incubation time. This process added an additional cycle to remove contaminants 
not removed during the washes and put BDNF-V40C2 at risk for more aggregation at 4◦C: 
additionally, ammonium chloride was used to salt out BDNF-V40C2. As before, there was a 
decrease in protein loss in hot supernatants and still a consistent loss of protein in cold pellets due 
to aggregation. Dimer formation in the 3rd cold spin supernatant and pellet are consistent with 
previous trials. Filtering BDNF-V40C2 prior to lyophilization is not advised due to the reduction 
of dimers. 
2.5 Discussion and Summary  
Our data has verified the formation and purification of Neurotrophin-ELP fusion proteins. 
Fusion of ELP sequence V40C2 with nerve growth factor and brain-derived neurotrophic factor 
allows for new paradigm shifts for the utilities of ELP [Johnson and Koria 2016]. Neurotrophins 
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can stimulate neuronal regeneration after injury; however they need a vehicle to allow sustained 
concentration at the site of injury [Katz and Burdick 2009]. As a result, ELP fusion proteins are a 
promising and therapeutic biopolymer for drug delivery [Kowalczyk et al. 2014]. 
Subsequently, throughout the purification process, protein solubility was challenged by 
consistent aggregation. Loss of protein in pellets may be due to the slow unfolding of nerve growth 
factor. Even in a high concentration, 5M GdnHCl, pro-NGF unfolds slowly and nerve growth 
factor truncated on its N-terminal side has a decreased time of unfolding [De Young et al. 1996]. 
For this reason, it is believed mature sequence unfolds quickly; however, Kliemannel et al. 
compared the unfolding of pro-sequence NGF (pro-NGF) to mature-NGF to find that the time the 
proteins unfold are similar with no indication as to why the neurotrophin slowly unfolds. De Young 
et al. believe the loop threading mechanism may have an effect on the unfolding of pro-NGF; 
however, Kliemannel et al. suggest the slowness of the unfolding process may have little to do 
with the loop threading mechanism that the protein undergoes while unfolding. De Young et al. 
ruled out the proline isomerization theory specifically because their thermodynamic results did not 
correspond to the observed activation energies of proline isomerization. However, Kliemannel et 
al. determined the activation energies of unfolding pro-NGF do fall in range for proline 
isomerization and cannot be ruled out as a possible reason for the slow unfolding. Kliemannel et 
al. also go further to suggest that if loop threading mechanism was at fault for the slow unfolding 
of pro-NGF, then it should have taken longer than the mature-NGF to get to the M2 state. Also, 
they believe refolding back to the native state should be inhibited because the loop would have to 
travel back through the cysteine knot [Kliemannel et al. 2006]. There has been much debate 
regarding the unfolding and refolding of neurotrophins. It is believed that the protein sequence is 
at fault although “the why” has not been agreed upon. Even the time period for a protein to unfold 
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is debatable. De Young et al. and Kliemannel et al. have determined it takes about a day for 
proNGF to unfold to the M2 state. However, previous works have solubilized inclusion body 
proteins in less than a day [Johnson and Koria 2016]. Consideration is taken that the IB protein 
may not be completely unfolded; further investigation needs to be done to determine whether the 
N-ELP fusion protein has unfolded to its M2 state without the pro-sequence and with the addition 
of an ELP. 
In our laboratory, we have discovered that BMP-2-ELP and EGF-ELP, are capable of being 
produced without the usage of denaturants. However, EGF-ELP aggregates at 4⸰C just as N-ELPs. 
Addition of a FLAG tag should increase solubility and reduce aggregation yet when the FLAG tag 
was fused to EGF-ELP, it still formed large aggregates at 4⸰C. EGF-ELP-FLAG tag did increase 
yield when compared to EGF-ELP yet the aggregation and protein loss was still abundant [Leonard 
2016]. It appears the FLAG tag allowed for more soluble protein to be expressed but it did not 
efficiently reduce aggregation throughout the purification process [Hwang et al. 2014, Rosano and 
Ceccarelli 2014]. Solubility fusion tags were developed to be a universal platform for the 
purification of recombinant protein. However, previous works have shown fusion tags to be 
protein-dependent. Fusion tags are widely used as detection tags that enable researchers to identify 
their target protein in diagnostic assays. However, in therapeutics, removing fusion tags from 
proteins that once formed inclusion bodies are not recommended due to the protein modifications 
that are caused by the harshness of the chemicals used during fusion tag removal [Hwang et al. 
2014, Rosano and Ceccarelli 2014]. Removing tags may be consequential for downstream 
application, interfere with immunogenicity, and decrease protein solubility which may be why 
pharmaceutical companies are reluctant to use them [Einhauer and Jungbauer 2001, Lebendiker 
and Danieli 2014]. GST is also prone to aggregation and has demonstrated poor solubility 
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enhancement capabilities. The aggregation and poor solubility are counter-productive to using 
GST as a solubility tag [Lebendiker and Danieli 2014, Rosano and Ceccarelli 2014]. Cleavage of 
FLAG tags and GST tags also contributes to increased production costs [Einhauer and Jungbauer 
2001, Lebendiker and Danieli 2014]. However, ELPs do not need to be removed for therapeutic 
delivery nor do they contribute to higher associated costs of tag removal; this is another reason 
why ELP fusion tags are an excellent choice [Kowalczyk et al. 2014]. 
ELP fusion tags can be fused in front of or behind the target protein. Christensen et al. 
demonstrated C-terminus ELP fusions of inclusion body prone proteins, protein-ELP construct, 
allow for a high expression of soluble lysate as well as a high expression of the fusion protein as 
inclusion bodies. Misfolded conformers with little to no activity may be included within this yield. 
However, the presence of the ELP tag allows recombinant protein to remain soluble throughout 
the purification process. Protein-ELP constructs demonstrate comparable functional activity when 
compared to unfused recombinant protein [Christensen et al. 2009]. However, diminished 
biological and functional activity has been seen in protein-ELP constructs when compared to 
unfused recombinant protein [Christensen et al. 2009, Johnson and Koria 2016]. 
Christensen et al.’s success may be due to their proteins of choice. Blue fluorescent protein, 
thioredoxin, and chloramphenicol transferase have fewer disulfide bonds than neurotrophins 
which decreases its chances of protein aggregation and misfolding. Several laboratories dedicate 
their research to the proper unfolding and refolding of inclusion body proteins. More than 88 
inclusion body protein have been studied in Dr. Amulya Kumar Panda’s laboratory and Dr. 
Xiaoning Wang’s laboratory [Zhang et al. 2009, Singh et al. 2015]. Like their colleagues, they 
mainly research IB proteins that form either one or two disulfide bonds. Each lab demonstrates a 
signature additive or technique for unfolding and refolding; however, there is limited information 
41 
on the proper unfolding and refolding of neurotrophins especially mature sequence neurotrophins 
attached to a fusion tag [Panda et al. 2008, Zhang et al. 2009, Yang et al. 2011, Singh et al. 2015]. 
Dr. Rainer Rudolph’s (deceased) lab, now Dr. Elisabeth Schwarz’s lab, has eloquently laid out 
proper procedure for unfolding and refolding pro-sequence NGF [Rattenholl et al. 2013]. 
However, our lab is focused on unfolding/refolding of mature sequence neurotrophins due to 
mature sequences proficiency for binding with the receptors responsible for signaling axonal 
regeneration.  
Developing the proper protocol is difficult. There is not an agreement between researchers 
on the proper method to solubilize the IB pellet. Their techniques vary with: the concentration (2M 
to 8M) of the denaturant, type (Urea or GdnHCl) of denaturant, temperature for solubilizing (heat 
adjusted for protein, -20⸰C, Rt), or the time (30 minutes to 24 hours) the IB pellet is exposed to the 
denaturant. They even vary in the refolding process with: the temperature, time, additives, and 
technique for refolding proteins [Lee et al. 2000, Panda et al. 2008, Rudolph et al. 2008, Sharma 
et al., 2008, Burgess 2009, Yang et al. 2011]. The few concepts that the prominent inclusion body 
researching labs agree on are: inclusion body formation promotes low protein recovery due to 
aggregation, alkaline pH is helpful for solubilization, and refolding around pH 8.5 is best for the 
redox system [Panda et al. 2008, Rudolph et al. 2008, Burgess 2009]. 
The most commonly used refolding techniques are refolding by dilution/dialysis, or drop-
wise/pulsatile dilution. The main disadvantages of reverse dilution, rapid dilution, and step-wise 
dialysis are the need of large volumes and the fact that each method is prone to aggregation simply 
because high concentration of the solubilized protein is involved in the process. The protein is free 
to interact with itself during the dilution or the removal of the denaturant. Adding the target protein 
drop-wise at a low concentration has seen a success in the reduction of aggregation and increase 
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in protein recovery [Khan et al. 1998, Burgess 2009, Singh et al. 2015]. Panda et al. uses this 
technique to develop their own pulsatile dilution by adding small amounts of protein to a large 
volume of refolding buffer. This technique helps inhibit aggregation because there is little protein 
in the volume to aggregate with and it ultimately improves the final recovery of proteins. [Singh 
et al. 2008]. Although this technique reduces aggregation, it also increases the production time and 
results in large volumes of liquids. These techniques are subsequently purified using 
chromatographic procedures in order to reduce the volume size [Lilie et al. 1998, Patra et al. 2000, 
Singh and Panda 2005]. A large volume of liquid is not ideal for non-chromatography purification. 
Rapid dilution calls for a total of 600mL [Burgess 2009] while pulsatile refolding can be done with 
a volume of 100mL [Singh et al. 2008]. To reduce these problems, the final volume may need to 
be reduced to 50mL or 100mL of purified refolded protein that will then be lyophilized. 
With this information, I have developed several purification and refolding protocols. 
Optimization is key but has been difficult to reach. When N-ELP fusions are being expressed and 
purified, they form IB proteins and are solubilized in 8M Urea. The strong denaturant is reduced 
via dialysis, undergoes three cycles of ITC, and is renatured via dialysis. During this process, 
protein solubility is challenged. There is abundant loss of protein in the hot supernatant and cold 
pellet of each cycle. Other works have also seen a decrease in yield with each cycle [Ge and Filipe 
2006]. Since aggregation increases with the removal of salts and denaturants [Rudolph and Lilie 
1996, Singh et al. 2015], we determined to use 2M Urea to keep the protein in its reduced state so 
that the protein does not have to unfold and refold before every cycle, thereby possibly reducing 
aggregation after removal of 8M Urea. However, despite usage of 2M Urea with 10mM DTT, in 
our study some protein remained in the hot supernatant due to the ELP transitioning property not 
being fully triggered by the ionic concentration or the temperature. Urea arrests the thermal activity 
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of ELP and increases the transition temperature of an ELP so increasing the ionic strength is 
necessary to efficiently trigger the phase transition property of the ELP fusion [Unpublished work]. 
The low ionic strength contributes to the low protein yield in this current model. Low protein yield 
is also contributed to the loss of protein in the cold pellet which may be due to protein aggregation 
at lower temperatures. Aggregation may be reduced with longer resuspension time and agitation. 
The longer resuspension time of the IB pellet and hot pellets may be necessary due to aggregation 
of its disulfide bonds [Rudolph and Lilie 1996]. The increased aggregation may be due to the 
original usage of a strong denaturant to solubilize the IB pellet and the removal via dialysis 
[Rudolph and Lilie 1996]. However, exposure of the IB Pellet to 8M Urea (strong denaturant) is 
limited to 30 minutes to an hour which in other works meant the protein had not completely 
unfolded. At that point it is stated to be in the M1 and on the way to the M2 state; the M2 
(completely unfolded) state is said to be accomplished at 24 hours [De Young et al. 1996, 
Kliemmanel et al. 2006]. Mild solubilization may be useful to reduce protein aggregation. The 
alkaline pH and 2M Urea destabilizes the hydrophobic and ionic interactions which are major 
causes of protein aggregation; however mild solubilization at an alkaline pH does not allow the 
protein to completely unfold and maintains native secondary structure which decreases the chances 
of protein aggregation [Singh et al. 2015]. Instilling a modified miniature pulsatile dilution method 
after each hot spin may be a promising addition to my current model. If longer incubating time is 
not successful, the temperature at which the cold spins take place may need to be increased high 
enough to not trigger aggregation but low enough to not trigger the ELP’s phase transition.  
Refolding a protein, especially a protein that contains disulfide bonds, may be difficult. 
Neurotrophins contain several disulfide bonds that upon refolding may bind with an incorrect 
sulfur atom, increasing the probability of aggregation [Taniyama et al. 1991, Nahri et al. 1993]. 
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Disulfide bonds can be reshuffled during the folding process and bind with a new sulfhydryl 
partner, resulting in an improperly folded protein [Singh et al. 2015]. During purification the 
disulfide bonds are stabilized with dithiothreitol (DTT). After purification and renaturation, the 
dialyzed protein is centrifuged at 4◦C prior to filtering to remove excess salts; however, some of 
the target protein was lost in the cold pellet (Figure 2.3) which suggests aggregation has not been 
reduced and additives such as arginine and GSH/GSSG may need to be used to assist in protein 
solubility. However, to circumvent this loss, I used sonication with each wash and 8M Urea and 
also used two 8M Urea spins to solubilize more protein from the IB Pellet. Refolding additives 
were used to demonstrate a profound dimer formation in N-ELPs (Figure 2.4A). Adding the 
refolding additives to the 8M Urea was beneficial to the protein not precipitating as the denaturant 
was removed however, there was still substantial loss in the cold pellet. All of the optimization 
done was beneficial to reducing loss in the hot supernatants as well as increasing protein recovery. 
Currently, N-ELPs exhibit solubility issues and need reducing agents and salts to help with 
their stability. To further our novel approach towards regenerating nerves, a further investigation 
of the solubility issues facing the N-ELP fusions must be conducted. With the consistent loss of 
protein due to aggregation, the yield is extremely low when compared to ELP fusions that do not 
need denaturants. The amount of protein recovered was sufficient for characterization studies and 
biological assays however, producing 30 mg of protein from a 1L batch is not ideal for a scale-up 
process. Despite aggregation of the N-ELP fusion proteins in each cycle, purification of the 
insoluble fractions was successful because of the phase transition property of ELPs. Based on the 
loss of protein in the hot supernatants and cold pellets, the concentration of DTT does not 
efficiently reduce aggregation. Perhaps using L-arginine or GSH/GSSG in congruence with the 
removal of the 8M Urea along with the usage of 2M Urea would be better so as to reduce the 
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aggregation of N-ELPs and promote proper refolding from the M2 to M1 and finally to the native 
state. Additionally, non-chromatographic affinity tags like elastin-like polypeptides reduce 
inclusion body formations and are attractive choices for protein recovery [Trabbic-Carlson et al. 
2004]. 
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Figure 2.1 Denaturant test for solubilizing NGF-V40C4. 2M-8M Urea was dissolved in 1X Tris 
buffer unless stated otherwise. 8M Urea in 1X Tris Buffer chosen to be denaturant for further 
testing. 1 – 2M Urea, 2 – 4M Urea, 3 – 6M Urea, 4 – 8M Urea, 5 – 8M Urea in DI water, 6 – 6M 
GdnHCl in DI water, B – Blank, M- Molecular Ladder. 
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Figure 2.2 Activating phase transition property of ELP fusion protein by removing 8M Urea. NGF-
V40C4 was expressed as an inclusion body protein and was denatured with 8M Urea. ITC was not 
effective without the removal of 8M Urea. NGF-V40C4 was lyophilized and partially soluble in 
PBS afterwards. All insoluble pellets were re-suspended in 8M Urea for western blot analysis 
unless otherwise stated. The expression of NGF-V40C4 was confirmed by western blot using an 
antibody reactive to NGF. Where, 1 – NGF-V40C4 IB Pellet, 2 – NGF-V40C4 IB Pellet, 3 – 
Denatured IB Pellet resuspended in D.I. water, 4 – Supernatant after dialysis, 5 – Supernatant after 
dialysis, 6 – Supernatant after water bath, 7 – Hot spin Supernatant, (Soluble Contaminant), 8 – 
Resuspended Hot spin Pellet in DI water before dialysis, 9 – Lyophilized Protein B – Blank, M – 
Molecular Ladder 
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Figure 2.3 Protein recovery low despite usage of lysis buffer, transition buffer, and DTT. 
NGFV40C4 was not reactive to the NGF antibody in the protein 3rd Cold spin supernatant as it 
should be (protein was lyophilized). Concentration may be low. Despite addition of DTT, 
aggregation of protein at low temperatures continues. The pellet prior to dialysis was re-suspended 
in 8M Urea for testing. ITC cycled pellets were re-suspended in 2M Urea. The expression of NGF-
V40C4 was confirmed by western blot using an antibody reactive to NGF. Where, 1 – Lysed 
supernatant, 2 – Cold denatured pellet, 3 – 8M Urea supernatant, 4 – Supernatant after dialysis, 5 
– 1st Hot supernatant, 6 – 1st Cycle cold pellet, 7 – 1st Cycle cold supernatant, 8 – 2nd Cycle hot 
supernatant part a, 9 – 2nd Cycle hot supernatant part b, 10 – 2nd Cycle cold pellet, 11 – 2nd Cycle 
cold supernatant, 12 – 3rd Cycle hot supernatant, 13 – 3rd Cycle cold pellet, 14 – 3rd Cycle cold 
supernatant before dialysis. 
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Figure 2.4 Refolding additives increase dimer formation in NGF-V40C2. Dimer formation 
increases after 24 hours (Lane 14A). A: Top) 10 – 3rd Hot Supernatant (Soluble Contaminant), 11 
– 3rd Cold Pellet (Insoluble Contaminant), 12 – 3rd Cold Supernatant (Soluble Protein), 13 – 
Refolded Additives Supernatant (Soluble Protein), 14 – Dialyzed Protein (Soluble Protein). B: 
Bottom) 1 – Washing buffer Supn (soluble protein), 2 – Washing buffer Supn (Soluble protein), 3 
– Lysis buffer Supn (Soluble Protein), 4 – 8M Urea, 10mM DTT Supernatant 1st Spin (Soluble 
Protein), 5 – 8M Urea, 10mM DTT Supernatant (Soluble Protein) 2nd Spin, 6 – 1st Cold Pellet 
(Insoluble Contaminant), 7 – 2nd cycle Cold Pellet (Insoluble Contaminant), 8 – 3rd Cycle Hot 
Supernatant (Soluble Contaminant), 9 – 3rd Cycle Cold Pellet (Insoluble Contaminant), 10 – 3rd 
Cycle Cold Supernatant (Soluble Protein), 11 – Refolded NGFV40C2, 12 – Dialyzed NGFV40C2, 
13 – Filtered NGFV40C2, 14 – Lyophilized NGFV40C2, M – Molecular Ladder. 
  
Trimer 
Dimer 
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Figure 2.5 Battle of the protocols. Refolding additives were added to 8M Urea to fold protein prior 
to inverse transition cycling. Long Haul: Time was extended for resuspension of pellets. Original 
Protocol: Without the refolding additives and short resuspension time. Refold: 1- 8M Urea 
Supernatant (Soluble Protein), 2 – After Refold Additives (Soluble Protein), 3 – After 3 day 
dialysis (Soluble Protein), 4 – 1st Cold Supernatant (Soluble Protein), 5 – 2nd Hot Supn (Soluble 
Contaminant), 6 – Lyophilized Protein in 1X PBS. Original: 7 – Lyophilized Protein in 1X PBS. 
Long Haul: 8 – 8M Urea Supn (Soluble Protein), 9 – Room temp dialysis (Soluble Protein), 10 – 
After 51 hour water bath at 25℃, 11 – 1st Cold Supn (Soluble Protein), 12 – 2nd Hot Supn (Soluble 
Contaminant), 13 – Lyophilized Protein in 1X PBS, 14 – Lyophilized Protein in 2M Urea, M – 
Molecular Ladder. Red ovals – Dimer Formation. 
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Figure 2.6 Strong ionic interactions decrease protein loss in hot supernatants. Filtration was 
replaced by centrifugation however, cold centrifugation after dialysis increases aggregation 
thereby reducing the protein yield while removing contaminants. Despite changes to the protocol, 
dimers and monomers are continuing being stuck in the cold pellets. 1 – 8M Urea pH 8 Supn 
(Soluble Protein), 2 – 8M Urea pH 3 Supn (Soluble Protein), 3 – 1st Cold Pellet (Insoluble 
Contaminant), 4 – 1st Hot Supn (Soluble Contaminant), 5 – 2nd Cold Supn (Soluble Protein), 6 – 
3rd Cold Supn (Soluble Protein), 7 – 3rd Cold Pellet (Insoluble Contaminant), 8 – Dialyzed 
NGFV40C2, 9 – Cold spin Pellet after dialysis, 10 – Cold spin Supernatant after dialysis. Red 
ovals – Dimer Formation. 
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Figure 2.7 BDNF-ELP dimerization after dialysis. PBS solubilizes soluble protein. All 
Lyophilized Proteins were resuspended in 2M Urea (1mg/mL). A) 1 – Inclusion Body Pellet 
(PBS), 2 – Lysed Supn, 3 – 8M Urea Supn, 4 – 1st Hot Supn, 5 – 1st Hot Supn (previous protocol 
with refolding additives and acidic pH), 6 – 2nd Hot Supn, 7 – 3rd Cold Supn, 8 – Supernatant 
before filtration, after dialysis. B) 1- Inclusion Body Pellet, 2 – 2nd Wash discard, 3 – 8M Urea 
Supn, 4 – 1st Hot Supn, 5 – 1st Cold Pellet, 6 – 4th Cold spin Supn, 7 – Filtered & Lyophilized 
BDNF-V40C2 (Original Protocol), 8 – Lyophilized BDNF-V40C2 (Ammonium Chloride Trial), 
9 – Lyophilized BDNF-V40C2 (freeze-thaw in 8M Urea), M – Molecular Ladder. Red ovals – 
Dimer Formation. 
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CHAPTER 3. PURIFYING BIOACTIVE PROTEINS AFTER FORMING INCLUSION 
BODIES WITHOUT THE NEED OF CHROMATOGRAPHY  
3.1 Note to Reader  
Part of this chapter was published in Johnson, T., Koria, P., Expression and purification of 
neurotrophin-elastin-like peptide fusion proteins for neural regeneration. BioDrugs, 2016. 30(2): 
pp.117-127. Permission is included in Appendix C. 
3.2 Purifying Inclusion Body Proteins  
Previous works have shown that purifying misfolded, inclusion body (IB) proteins is 
arduous and time-consuming. An IB protein must be solubilized with a high concentration of 
denaturant, refolded, and purified [Rattenholl et al. 2001, Johnson and Koria 2016]. Additives, 
such as dithiothreitol (DTT), reduced glutathione (GSH), and oxidized glutathione (GSSG) must 
be used to ensure proper folding [Lyons and Thomason 1995, Rudolph and Lilie 1996]. 
Purification of target protein takes place by the usage of chromatography [Hoppe et al. 1990] and 
inverse transition cycling [Johnson and Koria 2016]. Chromatography is widely known to produce 
and purify a high yield of bioactive protein after inclusion body formation, denaturation, and 
renaturation [Hoppe et al. 1990, Singh and Panda 2005].  
3.3 Purification Methods of Recombinant Proteins  
Recombinant proteins may be purified through several different methods [Wingfield 
2015]. One of the most common ways of purifying proteins is through column chromatography 
[Coskun 2016]. However, ELP fusion proteins are capable of being purified via inverse transition 
cycling. 
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3.3.1 Chromatography  
Proteins vary in different ways: composition, charge, or size [Coskun 2016]. 
Chromatography uses these differences to separate them from contaminants via a catch and release 
system. A column can “catch” a protein as it passes through it (stationary phase) until it is 
intentionally released (mobile phase) [Urh et al. 2009]. There are two main types of 
chromatography: liquid chromatography and gas chromatography [Coskun 2016]. Recombinant 
proteins are predominantly purified through various types of liquid chromatography: affinity 
chromatography, immobilized metal affinity chromatography, high performance liquid 
chromatography (HPLC), reverse-phase HPLC, or gel filtration/size exclusion chromatography 
(SEC) [Coskun 2016, Hage 1999, Urh et al. 2009].  
3.3.1.1 Affinity Chromatography  
Affinity chromatography separates molecules from complex mixtures through specific 
binding interactions, such as interactions between antibody and antigen, enzyme and substrate, or 
receptor and ligand [Hage 1999]. Electrostatic interactions between the ligand and the target 
protein allows reversibility of the binding so that the ligand can specifically bind to and release a 
protein. Washes are done to remove contaminants while the target protein remains bound to the 
column. Eluting the target protein with a competitive ligand elution buffer is considered to be 
specific elution. This method weakens the electrostatic interactions between the target protein and 
the affinity ligand. Non-specific elution of the target protein is done by changing the pH, salt 
concentration, or polarity of an elution buffer [Urh et al. 2009].  
Affinity chromatography has the capability of producing a high yield of bioactive protein 
because of the selectivity of its interactions. Due to the specificity of this method, proteins can be 
isolated from denaturants such as urea or guanidine hydrochloride, which are used to solubilize 
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inclusion body proteins. Affinity chromatography is able to capture and purify low concentration 
proteins from large volumes of crude sample [Bornhorst and Falke 2000]. Large volumes of buffer 
solutions are generally needed to renature a denatured protein. To assist in the detection and 
purification process of IB proteins, protein fusion tags, such as histidine-tag (His-tag), glutathione 
S-transferase tag (GST), or elastin-like polypeptides [ELP] are fused to recombinant proteins 
[Magdeldin and Moser 2012, Pina et al. 2014].  
3.3.1.1.1 Immobilized Metal Affinity Chromatography  
Immobilized Metal Affinity Chromatography (IMAC) utilizes an affinity ligand such as 
nickel (Ni) by immobilizing it onto a solid matrix such as agarose beads (stationary phase) via 
nitrilotriacetic acid (NTA) creating a Nickel-nitrilotriacetic acid (Ni-NTA) resin [Bornhorst and 
Falke 2000, Magdeldin and Moser 2012]. IMAC is a useful tool for producing a soluble, bioactive 
protein from insoluble aggregates [Holzinger et al. 1996, Bornhorst and Falke 2000]. Using a 
specified binding buffer (usually containing imidazole), the affinity ligand (nickel) will bind to the 
His-tag linked to the target protein [Bornhorst and Falke 2000, Magdeldin and Moser 2012]. 
Denatured proteins containing a His-tag can be passed through the Ni-NTA column because the 
electrostatic interactions are not dependent on the tertiary structure of the protein [Holzinger et al. 
1996, Bornhorst and Falke 2000]. A high concentration of imidazole or free ligand in the elution 
buffer can be passed through the column to specifically elute the target protein. The imidazole will 
displace the His-tag of the target protein, thereby breaking its bond with the column [Bornhorst 
and Falke 2000, Magdeldin and Moser 2012]. This technique is intriguing for its ability to renature, 
refold and purify a denatured protein within the column [Bornhorst and Falke 2000, Oganesyan et 
al. 2004, Pina et al. 2014]. Strong reducing agents such as dithiotreitol (DTT) [Kimple 2013] or 
strong chelating agents such as ethylenediaminetetraacetic acid (EDTA) [Bornhorst and Falke 
60 
2000] are commonly used in solubilizing, cell lysis, or refolding buffers for inclusion body 
denaturation; however, they should not be used in affinity chromatography. These agents reduce 
the nickel ions and can strip them from the column [Kimple 2013, Bornhorst and Falke 2000], 
thereby diminishing the target protein’s ability to bind with the column.  
3.3.1.2 High-Performance Liquid Chromatography  
Affinity columns can be used in conjunction with high-performance liquid chromatography 
(HPLC) and reverse-phase high-performance liquid Chromatography (RP-HPLC). HPLC is 
effective for separating compounds based on their hydrophilicity. The packing material for the 
stationary phase would have a high polarity, whereas the solvent of the mobile phase would be a 
hydrophobic, low polar substance. HPLC has many advantages: low sample consumption, highly 
sensitive, selective hydrogen bonding and decreased retention time. However, proteins within the 
column are prone to fluctuations in retention time in response to the target protein stabilizing 
slowly. In addition, purchasing the best eluent to stabilize the target protein can be expensive. The 
HPLC instrumentation itself is expensive; it contains, detector, pump, solvent reservoir, column, 
sample injector, and display system. Unlike most columns, HPLC is conducted under high 
pressure. The solvent is forced through the column to separate different molecules within the 
column [Thammana 2016].  
3.3.1.2.1 Reverse-Phase High-Performance Liquid Chromatography  
Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) separate proteins 
based on their hydrophobicity. Depending on the peptide or the protein, an ideal column is 
composed of hydrophobic compounds such as the commonly used ligands; n-alkyl, n-butyl, and 
n-octadecyl silica ligands. The longer the chain length, the stronger the bond [Aguilar 2004]. A 
non-polar, hydrophobic protein will bind amenably to a hydrophobic column and will need a polar, 
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hydrophilic elution buffer (water, acetonitrile, and/or methanol) to elute the target protein [Aguilar 
2004, Thammana 2016]. Each commonly used ligand is accompanied with a few disadvantages: 
increased retention time, poor protein recovery, degraded conformational integrity, or affinity to 
acidic buffers. RP-HPLC is a selective method capable of producing a high yield of protein. 
However, it may cause irreversible denaturation of a protein. This is not ideal for inclusion body 
proteins being their goal is to be renatured. [Aguilar 2004].  
3.3.1.3 Size-Exclusion Chromatography  
Size-exclusion chromatography (SEC) separates proteins on the basis of their size. The 
column is packed with a matrix of fine porous beads. The smaller molecules enter the pores and 
elute slower. The larger molecules pass quickly through the column and are eluted first. Size-
exclusion chromatography can be coupled with HPLC and light scattering to detect a sample’s 
molecular weight, conformation, aggregation, and general molecular structure. There are two basic 
types of SEC: gel permeation chromatography (GPC) and gel filtration chromatography (GFC) 
[Hong et al. 2012]. SEC can be used in the presence of denaturants, and inclusion body proteins 
can be separated from the crude sample. The target protein can also be renatured within the column 
prior to elution [Müller 1999, Yang et al. 2011].   
3.3.2 Inverse Transition Cycling  
Inverse transition cycling (ITC) is a bioseparation technology useful for purifying 
recombinant proteins. Recombinant proteins linked to elastin-like polypeptides can be expressed 
in bacteria and purified to high homogeneity by utilizing the ELPs’ reversible inverse phase 
transitioning property (Figure B.2) [Trabbic-Carlson et al. 2004, Hassouneh et al. 2010, 
Kowalczyk et al. 2014]. The inverse phase transitioning property can be triggered by changing the 
solution temperature, pH, or the ionic composition of a buffer during ITC. ITC can be optimized 
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specifically for various ELP fusion proteins, thereby increasing expression and separation 
efficiency of a target protein [Christensen et al. 2013, Kowalczyk et al. 2014]. This advantageous 
strategy is useful for inclusion body proteins whose purified yield is lower than non-aggregated 
proteins [Leonard 2016, McCarthy et al. 2016]. ITC can also be carried out under denatured 
conditions for inclusion body proteins [Johnson and Koria 2016].  
Inverse transition cycling separates a target protein from the bacterial cell lysate by 
stimulating the ELP via a temperature-induced phase change. At temperatures below a protein’s 
lower critical solution temperature (LCST), the protein is deemed soluble and will remain in the 
aqueous solution after centrifugation (cold spin). Whereas, when a protein reaches above the 
LCST, the ELP target protein is entropically driven insoluble and is, thereby, separated from the 
soluble impurities (hot spin) [Christensen et al. 2013, MacEwan et al. 2014]. Salt may also be used 
to trigger the inverse transition phase of the protein prior to the hot spin. The soluble impurities 
are then decanted from the pellet. Solubilizing the pellet and repeating the process will yield a 
seemingly pure protein [Meyer and Chilkoti 2002, Trabbic-Carlson et al. 2004]. Dialysis and 
filtration may be used to remove the salts, DTT, and other additives used during the purification 
process [Meyer and Chilkoti 2002, Trabbic-Carlson et al. 2004, Hassouneh et al. 2010]. 
Purification of ELPs through ITC is economically advantageous in both time and expense when 
compared to the chromatographic methods; large-scale production of a target protein can also be 
accomplished via ITC [Hassouneh et al. 2010, Trabbic-Carlson et al. 2004, Kowalczyk et al. 2014] 
as well as high-throughput applications of several different proteins simultaneously [Trabbic-
Carlson et al. 2004].   
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3.4 Analysis  
Affinity chromatography is usually not used in industrial scale protein purification because 
of the disadvantages that may lead to end-product contamination [Ge and Filipe 2006]. Increased 
costs and difficulties scaling up protein production can be caused by metal leaching, nonspecific 
hydrophobic interactions, improper disulfide bonding, and specific binding of non-targeted amino 
acids and imidazolyl, which may call for additional steps of purification [Bornhorst and Falke 
2000, Ge and Filipe 2006, Pina et al. 2014, Rudolph and Lilie 1996]. Concerning purifying 
inclusion body proteins with affinity chromatography; chelating agents and reducing agents are 
used in low concentrations due to exorbitant costs as well as their ability to strip the nickel within 
the resin [Rudolph and Lilie 1996, Bornhorst and Falke 2000, Manual 2005, Singh et al. 2015]. 
However, without reducing agents such as DTT, denatured proteins are prone to form improper 
disulfide bonds [Rudolph and Lilie 1996]. When in the affinity column, a denatured protein with 
exposed cysteine bonds can bind with other unwanted proteins creating a larger aggregate and 
contributing to end-product contamination. The adsorbents used in IMAC not only bind to 
histidines, but can also bind to other amino acids; specifically amino acids that are charged, consist 
of high pKa values, or contain a sulfur group. This unintended binding may result in low selectivity 
of the target protein. The biological activity of the target protein may be reduced due to the 
histidine side chain of imidazolyl interfering with proper protein folding as well as [Pina et al. 
2014] nonspecific hydrophobic interactions causing some co-purification with the target protein 
[Bornhorst and Falke 2000]. If the ligand is coupled with a large surface area of the resin, then 
irreversible, nonspecific hydrophobic interactions may occur which may result in a loss of the 
target protein [Ge and Filipe].  
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Ni-NTA is used in conjunction with various types of column chromatography (SEC, RP-
HPLC, AC) to increase binding of the target protein. However, nitrilotriacetate (Fe-NTA, Cu-
NTA) has been linked to cancer, specifically renal cancer [Toyokuni et al. 1996, Rashid et al. 
2013]. Despite this issue, column chromatography has been able to produce and purify a high yield 
of bioactive protein after inclusion body formation, denaturation, and renaturation [Müller and 
Rinas 1999, Sharma et al. 2008, Zhang et al. 2009]. Holzinger et al. found Immobilized Metal 
Affinity Chromatography to be protein-dependent. For certain recombinant proteins, slow removal 
of denaturants were not required to produce a bioactive protein whereas, other recombinant 
proteins were inefficiently renatured or not capable of complete renaturation [Holzinger et al. 
1996]. Despite the advantages IMAC can bring; an inefficient protocol is not effective for 
renaturing, refolding, and purifying an insoluble aggregate. Ecballium elaterium trypsin inhibitor 
II (EETI-II) is a cysteine-knot growth factor that forms inclusion bodies [Wentzel et al. 1999]. Gao 
et al. have developed a purification protocol for EETI-II using a histidine tag (His-tag), 
Glutathione-S-Transferase (GST) tag, nickel-nitrilotriacetic acid (Ni-NTA), specific elution with 
high concentration of imidazole, and RP-HPLC. All of these techniques were used in conjunction 
to increase solubility, to avoid inclusion body formation (GST), for targeted binding (His-tag to 
Ni-NTA), and for purification (RP-HPLC) [Gao et al. 2016]. Gao et al.’s technique is impressive, 
yet expensive. Müller and Rinas utilized SEC to separate, pre-purify, and renature a high yield of 
heterodimer PDGF-A/B. Once again, inclusion body proteins have been shown to be capable of 
being renatured within the column and with the addition of heparin chromatography and heparin 
sepharose affinity resin, monomeric PDGF can be removed from the heterodimer [Müller and 
Rinas 1999]. It is common to combine usage of various column chromatography for purification 
and renaturation of aggregates; however, it is still an expensive operation [Rudolph and Lilie1996, 
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Müller and Rinas 1999, Sharma et al. 2008]. Column chromatography can also be time-consuming 
and technically challenging. Inverse transition cycling is an effective alternative method for 
purifying recombinant proteins. ITC is cost-efficient, time-efficient, and not technically 
challenging. In a laboratory setting, economic and technical challenges are considered for high 
capacity scale-up production. This necessary consideration is the reason that inverse transition 
cycling is the method of choice for laboratories. ITC requires no additional equipment or reagents 
to produce a high yield of protein that can be more than 95 percent pure [Trabbic-Carlson et al. 
2004, Christensen et al. 2009, Hassouneh et al. 2010]. Trabbic-Carlson et al. have also shown that 
proteins produced by ITC can reach the same level of purity as recombinant proteins produced by 
IMAC with an additional increase in efficiency. Protein yields in column chromatography are 
limited by the loading capacity of the resin which will increase the cost of protein production 
[Christensen et al. 2009]. However, there are challenges in producing a high-yield of protein after 
denaturation without the usage of column chromatography [Johnson and Koria 2016].  
3.5 Expression and Purification of Elastin-Like Polypeptide Fusion Proteins 
 Chapter 2 discussed an extensive process of purifying N-ELP fusion proteins. The 
following section used some of the techniques of Chapter 2 except instead of Tris Buffers for the 
solubilization and transition buffer, 1X PBS is the used. Also, spoiler alert, all of the purification 
trials for NGF-V40C2 and BDNF-V40C2 produced functional, bioactive protein. 
3.5.1 Material and Methods  
3.5.1.1 Synthesis of Genes Encoding Neurotrophin-ELP Fusion Proteins  
The PUC57 plasmid containing the gene encoding recombinant human NGF (UniProtKB-
P01138, Ser122-Ala241) and BDNF (UniProtKB-P23560, His129-Arg247) that was used in this 
study were purchased from GenScript. The PUC19 plasmid containing the elastin cassette V40C2 
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has been described previously [Koria et al. 2011]. We used PflMI and BglI enzymes to excise the 
gene fragment encoding recombinant NGF or BDNF from the PUC57 plasmid. The excised gene 
fragments were cloned in frame in the plasmid containing the elastin cassette to create a gene 
encoding either NGF-ELP or BDNF-ELP as described previously [Meyer and Chilkoti 2002, Koria 
et al. 2011]. The gene encoding the fusion proteins was then excised from the PUC19 plasmid and 
inserted into the expression plasmid pET25b+ for protein expression.   
3.5.1.2 Expression and Purification of Neurotrophin-ELPs  
The expression vector pET25b+ containing NGF-ELP or BDNF-ELP was transformed into 
E.coli BLR (DE3) cells through heat shock at 42◦C. A starter culture of 75mL was then inoculated 
overnight and added to a 1L culture the next day. The 1L culture was then propagated overnight. 
The next day, bacterial cells were harvested by centrifugation (3000g, 20 minutes) at 4◦C. After 
two washes with washing buffer (50mM Tris Base, 10% Glycerol, 1% Triton X-100, 50mM DTT, 
and 1mM EDTA), the bacterial cells were lysed by sonic disruption on ice (6 cycles, 50% 
amplitude, and 30 seconds on/off). The solution was centrifuged (20,000g, 15 minutes) and the 
pellet containing the inclusion bodied protein was collected while the supernatant was discarded. 
The pellet was re-suspended in lysis buffer (50mM Tris Base, 10% Glycerol, 1% Triton X-100, 
50mM DTT, 1mM EDTA, 100ug/mL Lysozyme, and 100mM NaCl) followed by sonication on 
ice (3 cycles, 50% amplitude, and 10 seconds on/off). The sonicated mixture was centrifuged again 
and the pellet was collected. This pellet was re-suspended in solubilization buffer (8M Urea + 
10mM DTT, 1X PBS, pH 3.0) followed by sonication on ice to assist in the solubilization of the 
inclusion bodies. After another round of centrifugation, the supernatant containing the ELP fusion 
proteins was transferred to a clean centrifuge tube. The pellet was re-suspended once more in the 
solubilization buffer and another round of centrifugation was performed. The supernatant 
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containing the fusion protein was dialyzed overnight against 2M Urea. The next day 1M NaCl was 
added to the dialyzed supernatant and heated to 40◦C to enable the transition of the fusion protein. 
A hot spin at 40◦C was performed to pellet the fusion protein. The supernatant was then discarded, 
and the pellet was re-solubilized in a Transition Buffer (2M Urea + 10mM DTT, 1X PBS, pH9.5) 
on ice followed by another cold spin at 4◦C. The pellet was discarded and the supernatant was 
collected to complete one purification cycle. This cycle was repeated twice for a total of three 
cycles. For the final re-suspension step, the fusion protein was re-suspended in 2M Urea and then 
dialyzed overnight against deionized water at 4◦C. The purified NGF-ELP and BDNF-ELP 
proteins were then lyophilized the next day for storage.   
3.5.1.3 Characterization of the Fusion Proteins  
The purity and solubility of recombinant proteins were analyzed by electrophoresis on a 
15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing 
conditions. The Protein Stain was performed according to the gelcode blue safe protein stain 
protocol (Thermo Scientific) and Western-blotting was performed with NGF antibody (Cell 
Signaling, 1:1000) or BDNF antibody (R&D Systems, 1:100).  
Lyophilized protein was re-suspended in phosphate buffered saline (PBS) at a 
concentration of 1mg/mL and particle sizes at different temperatures were measured by dynamic 
light scattering using a zeta-sizer (Malvern instruments).  
3.5.1.4 Neurite Outgrowth Assay  
PC12 cells were seeded in poly-L-lysine treated 24-well plates at the density of 400,000 
cells/mL and maintained under RPMI 1640 (5% fetal bovine serum, 10% heat-inactivated horse 
serum, 1% AA) at 37◦C for 7 days.  Prior to seeding, the wells were coated with PLL for 2 hours 
and then washed with PBS.  Every two days the cells were treated with 1mg/mL NGF-ELP or 50 
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ng/mL recombinant NGF. PC12 cells containing neurite extensions were counted and averaged 
over the total number of PC12 cells in a frame.  
3.5.1.5 TrkB Phosphorylation Assay  
HEK 293-T cells were seeded in 24-well plates at the density of 200,000 cells/well and 
maintained under DMES. Transfection of the cells was carried out with a DNA solution containing 
2M Calcium Chloride, nuclease water, 2X HBS, 25 uM Chloroquine, and .25 ug pEGFP TrkB 
Plasmid (Addgene) or 0.25ug of pCDNA TrkB Plasmid (Addgene). The plasmid solution was 
added to the cells and incubated for 2 hours.  The solution was removed and the cells were washed 
once with PBS, followed by addition of fresh DMEM. After two days the cells were treated with 
either 1mg/mL BDNF-ELP, ELP, no treatment (control) or 50 ng/mL recombinant BDNF for 15 
minutes.  After treatment the cells were lysed in lysis buffer (3X sample buffer from cell signaling 
technology, nuclease free water, 30X DTT, Protease/Phosphatase Inhibitors). The lysates were 
subjected to western blots using either Phospho TrkB antibody (Cell signaling Technology, 
1:1000) or TrkB antibody (1:1000, Cell signaling Technology).   
3.5.1.6 Molecular Weight of Neurotrophin-ELP  
Recombinant nerve growth factor (NGF) and recombinant brain-derived neurotrophic 
factor (BDNF) Molecular Weight = 13kDa (monomer). V40C2 = ELP = 20.5 kDa. NGF-ELP and 
BDNF-ELP molecular weight = 33.5kDa (monomer). NGF and BDNF behave as homodimers 
when active.  
3.5.1.7 RNA Isolation and Real-Time Polymerase Chain Reaction (RT-PCR) Analysis  
PC12 cells (400,000/well) were seeded in poly-L-lysine treated 6-well plates and treated 
every 2 days for 7 days with 1 mg/mL NGF-ELP or 50 ng/mL recombinant NGF. RNA was 
isolated from PC12 cells using the SV Total RNA Isolation System (Promega cat #Z3100). cDNA 
69 
synthesis was done using iScript cDNA Synthesis Kit from Bio-Rad (cat # 1708890) following 
manufacturer’s protocol. RT-PCR was performed using Bio-Rad C1000 thermal cycler. The 
following primers were used for PCR β3-tubulin: forward 5′-TCTACGACATCTGCTTCCGC-3′, 
reverse 5′-GTCGAACATCTGCTGGGTGA-3′ (40 PCR cycles). GAP43: forward 5′-
CAGGAAAGATCCCAAGTCCA-3′, reverse 5′-GAACGGAACATTGCACACAC-3′ (40 PCR 
cycles). GAPDH: forward 5′-CCTGCACCACCAACTGCTTA-3′, reverse 5′-
GCCTGCTTCACCACCTTCTT-3′.  
3.5.1.8 Statistical Analysis  
In the case of neurite outgrowth analysis, the differences in various conditions were 
assessed by means of ANOVA single factor. For comparisons between two groups, the one-tailed 
test was employed, and in all cases, a value of *p < 0.05 was considered to be statistically 
significant.  
3.5.2 Results  
As shown, we have produced bioactive protein from inclusion bodies using inverse 
temperature cycling (ITC). The fusion proteins, NGF-V40C2 and BDNF-V40C2 labeled as NGF-
ELP and BDNF-ELP, were expressed in bacteria as inclusion bodies. Both fusion proteins were 
purified successfully to high homogeneity. The fusion proteins self-assembled into nanoparticles 
at their respective transition temperatures. Moreover, in vitro cell culture assays showed that the 
biological activities of the fused neurotrophins were retained in the nanoparticles. Therefore, 
expensive refolding on a column was not necessary for the N-ELP fusion proteins’ functionality. 
Thus, these fusion proteins are useful for neural regeneration as they not only retain the biological 
activity of the neurotrophin but also self-assemble into nanoparticles; thereby simultaneously 
serving as drug delivery vehicles.   
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3.5.2.1 Neurotrophin-ELP Fusion Proteins are Expressed in Bacteria as Inclusion Bodies  
The genes encoding recombinant NGF and BDNF were cloned at the N-terminus of the 
ELP variant (VPGVG)40(VPGVGVPGVGVPGCGVPGVGVPGVG)2 to create two genes 
encoding proteins of the form NGF-ELP and BDNF-ELP (Figure 3.1). The two genes encoding 
the fusion proteins were cloned into the modified pET25b+ expression plasmid for protein 
expression in bacterial cells (BLR strain). Western blots using antibody specific to the 
neurotrophins demonstrated the successful expression of the proteins in bacterial cells. 
Interestingly, these fusion proteins were expressed as inclusion bodies (Figure 3.2A and 3.2B).  
3.5.2.2 Purification of Neurotrophin-ELP Fusion Proteins Using Inverse Transition Cycling  
ELP fusion proteins have typically been shown to be purified by exploiting their phase 
transition properties using a series of hot and cold spins [Meyer and Chilkoti 1999]. However, in 
order for this process to be successful, the fusion protein needs to be soluble in aqueous solution. 
So, in order to solubilize the inclusion bodies, 8M urea was used as a denaturant, which solubilized 
them (Figure 3.2A and 3.2B). But, since urea is a denaturant the fusion proteins will not transition 
in the presence of 8M urea, so urea was removed using dialysis overnight. The fusion proteins 
remained soluble after the removal of urea and transitioned when the temperature was increased. 
Thus, a hot spin was used to spin down the fusion protein. However, for re-suspension of the pellet 
a lower concentration of 2M urea was used to solubilize the fusion proteins successfully (Figure 
3.2A and 3.2B). This process completed one full cycle of ITC and it was repeated three more times 
to constitute a total of four cycles of ITC that yielded a highly purified protein (Figure 3.2C and 
3.2D). Western blots using antibodies specific to NGF and BDNF respectively demonstrated that 
the purified protein was indeed the neurotrophin-ELP (Figure 3.2A and 3.2B). Thus, the slight 
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modification of ITC by employing urea successfully yielded purified fusion proteins after forming 
inclusion body proteins. 
3.5.2.3 Neurotrophin-ELP Fusion Proteins Self-Assemble into Nanoparticles at the 
Transition Temperature  
Our successful purification of both NGF-ELP and BDNF-ELP; indicates that the physical 
phase transitioning property of ELPs was still retained into the fusion. The lyophilized proteins 
formed loose aggregates in the aqueous solutions at lower temperatures (Figure 3.3A and 3.3B, 
red line, 4◦C, 1mg/mL). Interestingly, when the temperature was increased beyond the transition 
temperature, both fusion proteins self-assembled into nanoparticles. These nanoparticles were 
fairly mono-dispersed with NGF-ELP displaying a peak at 199 nm and BDNF-ELP displaying a 
peak at 124 nm (Figure 3.3A and 3.3B, green line).   
3.5.2.4 Neurotrophin-ELP Fusion Proteins Retain the Biological Activity of the Fused 
Neurotrophin  
Finally, we evaluated the biological activity of the fused neurotrophin using in vitro cell 
culture models. NGF has been shown to promote differentiation and neurite outgrowth of PC12 
cells, a clonal cell line derived from a rat pheochromocytoma. When NGF is introduced to PC12 
Cells, the cells cease dividing followed by neurite extension within a week [Greene and Tischler 
1976]. Cells treated with NGF-ELP and recombinant NGF remained attached and displayed 
neurite outgrowth (Figure 3.4A, 3.4D), while no attachment or neurite outgrowth was observed in 
cells treated with ELP alone or with no treatment (Figure 3.4B, 3.4C). We further quantified the 
number of differentiated cells and found the NGF-ELP induced neurite outgrowth in PC-12 cells, 
though the number of differentiated cells was less than induced by recombinant NGF (Figure 3.5). 
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Negative control (ELP) exhibits no differentiation. * p<0.05, when compared with the indicated 
samples.  
We used human epithelial kidney cells (HEK 293) transfected with the TrkB-GFP fusion 
plasmid for the evaluation of the biological activity of BDNF which binds to the human 
Tropomycin receptor kinase B (TrkB) with high affinity resulting in its phosphorylation [Soppet 
et al. 1991]. Indeed similar to recombinant BDNF, the BDNF-ELP fusion induced phosphorylation 
of the TrkB receptor (Figure 3.6) in the transfected cells; while very little or no phosphorylation 
was seen in the control or ELP samples. These data clearly indicate that the biological activity of 
BDNF was retained in the fusion protein.  
3.5.2.5 Nerve Growth Factor-ELP Expresses Elevated Levels of Genes Related to Neuronal 
Differentiation  
The effect of NGF-ELP at the molecular level was examined. The levels of expression of 
genes related to neuronal differentiation, GAP43 and β3-tubulin, were studied. RNA was extracted 
from cells treated with NGF-ELP and compared to recombinant NGF as well as cells that received 
no treatment. PCR experiments revealed an elevated level of expression of GAP43 and β3-tubulin 
genes in cell populations treated with the NGF-ELP, in comparison with no treatment and 
comparable to recombinant NGF (Figure 3.7). As a loading control, the level of expression of 
GAPDH was examined. Figure 2.8 shows minimal difference in levels of expression of GAPDH 
for the samples.  
3.6 Discussion and Summary  
Extracellular growth factors stimulate cell growth. Cysteine-knot growth factors are known 
to forming inclusion body proteins in prokaryotic hosts as well as in mammalian and viral hosts. 
Cysteine-knot growth factors fused with an elastin-like polypeptide are capable of being purified 
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with the ITC method [George et al. 2015, Johnson and Koria 2016, Leonard 2016, McCarthy et al. 
2016]. Chromatographic methods were not required for protein recovery. These unique fusion tags 
can easily overcome the drawbacks associated with affinity chromatography and present high 
potential as large-scale purification platforms [Trabbic-Carlson et al. 2004]. Our preliminary data 
has verified the formation and purification of Neurotrophin-ELP fusion proteins. However, the 
yield was negatively impacted due to the aggregation of the neurotrophin-ELP fusion proteins 
during the purification process. Despite the solubility issues, NGF-V40C2 and BDNF-V40C2 are 
bioactive [Johnson and Koria 2016].  
Elastin-like polypeptides and their fusion proteins are often smaller at low temperatures 
however, as we saw in the results section of Chapter 2 and in the DLS results (Figure 3.4A, 3.4B), 
N-ELP and other CKGFs have demonstrated large aggregates at low temperatures [Johnson and 
Koria 2016, Leonard 2016], possibly because of free monomers aggregating with the protein. 
Furthermore, the only additive used in this purification method was DTT. Additional additives 
were not used due to the increased time and extra steps needed during the refolding process. 
Removing these steps decreased protein production time and still produced a bioactive protein. 
The amount of protein recovered after purification is comparable to when additional additives were 
used. However, without the usage of arginine and GSH/GSSG dimer formation is reduced thus 
leading back to the free monomers aggregating with the protein. This reaction may mean the 
protein is partially folded. However, the functional aspect of ELP is conserved (Figure 3.3A, 3.3B) 
as is the biological activity of the neurotrophins (Figure 3.4A, 3.5, 3.6, 3.7). BDNF-ELP was 
capable of phosphorylating the TrkB receptor, demonstrating that BDNF-ELP can be internalized 
via the high affinity receptor, thereby stimulating nerve repair. NGF-ELP stimulated neurite 
extension in PC12 cells which demonstrates its capabilities to interact with neuronal cells [Greene 
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and Tischler 1976, Soppet et al. 1991]. NGF-ELP also induced the molecular levels of expression, 
GAP43 and β3-tubulin. GAP43 plays a major role in neurite formation and regeneration 
[Kobayashi et al. 1997, Gupta et al. 2009] while β3-tubulin is a microtubule related to neurite 
outgrowth and neuronal differentiation [Caceres et al. 1986, Maioli et al. 2015]. Inducing these 
genes suggests that NGF-ELP can be internalized into neuronal cells to induce axonal growth. 
With the biological activity intact, a different purification protocol may be necessary to reduce 
aggregation and increase the yield of the N-ELP fusion proteins.  
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Figure 3.1 Recombinant Neurotrophin-ELP fusion proteins. Nerve growth factor-elastin like 
polypeptide (NGF-ELP) contains the 120 amino acid sequence of the mature NGF fused in frame 
at the N-terminus of the elastin-like peptide (ELP) sequence V40C2, where V=VPGVG and 
C=(VPGVG)2VPGCG(VPGVG)2. Brain-derived neurotrophic factor-elastin like polypeptide 
(BDNF-ELP) contains the 120 amino acid sequence of the mature BDNF fused in frame at the N-
terminus of the ELP sequence V40C2, where V=VPGVG and C=(VPGVG)2VPGCG(VPGVG)2.  
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Figure 3.2 Expression and purification of the Neurotrophin-ELP fusion proteins. A) Successful 
expression of NGF-ELP in bacteria and it gets accumulated in inclusion bodies. The expression of 
NGF-ELP was confirmed by western blot using an antibody reactive to NGF. Where, IB – 
Inclusion Body, 1 – 8M Urea, 2 – After Dialysis, 3 – 1st Cycle Cold Supernatant, 4 –Lyophilized 
NGF-ELP, M – Ladder. B) Successful expression of BDNF-ELP in bacteria and it gets 
accumulated in inclusion bodies. The expression of BDNF-ELP was confirmed by western blot 
using an antibody reactive to BDNF. IBB –Inclusion Body BDNF-ELP, 5 – 8M Urea, 6 – After 
Dialysis Overnight, 7 – 2nd Cold Supernatant, 8 – Lyophilized BDNF-ELP, M – Ladder. C) 
Successful purification of NGF-ELP from inclusion bodies as shown by a total protein stain. The 
final lyophilized product just represents one single band that was reactive to NGF antibody as 
shown in (A). D) Successful purification of BDNF-ELP from inclusion bodies as shown by a total 
protein stain. The final lyophilized product just represents one single band that was reactive to 
BDNF antibody as shown in (B).  
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Figure 3.3 Neurotrophin-ELP fusion proteins self-assemble into monodispersed nanoparticles at 
physiological temperature. A) NGF-ELP and B) BDNF-ELP formed loose aggregates at 4◦C (red). 
When the temperature was raised the 37◦C (green) A) NGF-ELP and B) BDNF-ELP self-
assembled into nanoparticles with a diameter of 199 nm and 124 nm respectively. The lyophilized 
proteins were dissolved in phosphate buffered saline and particle sizes were measured by dynamic 
light scattering.  
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Figure 3.4 NGF-ELP induces neurite extension in PC12 cells thereby retaining the biological 
activity in the fusion. Micrographs of PC12 cells cultured in the presence of A) 1 mg/ml NGF- 
ELP, B) 1 mg/ml ELP, C) no treatment (control) and D) 50 ng/ml of recombinant nerve growth 
factor (NGF) for 7 days were taken with EVOS™ fl Digital Inverted Fluorescence Microscope. 
PC12 cells were seeded and then treated every two days. Red arrows show neurite differentiation 
and neurite extension.  
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Figure 3.5 Quantification of differentiated cells induced by NGF-ELP and recombinant NGF. A 
ratio was taken of the amount of cells represented in an image that have differentiated (cells with 
at least one neurite with a length equal to the cell body diameter) vs. the total cells present. Cells 
were counted on Day 0, Day 4, Day 7. On Day 0 there is no differentiation between the three 
treatments. Day 4 cells begin to differentiate. Day 7 the amount of differentiated cells increased. 
Negative control (ELP) exhibits no differentiation. *p<0.05, when compared with the indicated 
samples.  
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Figure 3.6 Biological activity of Brain-derived neurotrophic factor (BDNF) in the BDNF-ELP 
fusion is retained. 293T cells were transfected with a plasmid containing the Tropomycin receptor 
kinase B (TrkB). Cells were then treated with the indicated treatments for 15 minutes followed by 
preparation of cell lysates. The cell lysates subjected to western blots using either an antibody 
specific to Trk-B (Left) or Phospho TrkB (Right) antibody.  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
85 
 
  
  
  
  
  
Figure 3.7 Effect of NGF-ELP on neuronal differentiation genes. PCR for mRNA levels of β3-
tubulin and GAP43: (1-No treatment (Control) Tubulin, 2-No treatment (Control) Tubulin, 3-
recombinant NGF Tubulin, 4-recombinant NGF Tubulin, 5-NGF-ELP Tubulin, 6-NGF-ELP 
Tubulin, 7-recombinant NGF GAP43, 8-NGF-ELP GAP43). As a loading control, the level of 
expression of GAPDH was examined: (1-No treatment (Control) GAPDH, 2-No treatment 
(Control) GAPDH, 3-recombinant NGF GAPDH, 4-recombinant NGF GAPDH, 5-NGF-ELP 
GAPDH, 6-NGF-ELP GAPDH, 7-recombinant NGF GAPDH, 8-NGF-ELP GAPDH) of 
differentiated PC12 cells treated with no treatment, recombinant NGF, and NGF-ELP. The panels 
to the right present a control PCR of GAPDH of the same samples. Data were obtained one day 
after treatment and 7-days after treatment.  
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CHAPTER 4. PROTEIN OF CHOICE  
4.1 Pro-Sequence Role in Protein Folding  
Mature sequence growth factors are habitually used as components in fusion proteins and 
are preferred for ligand-receptor binding at the cellular level. Non-mature, pro-sequence, 
neurotrophins have a higher affinity for binding to p75; p75 is the low receptor that mediates 
apoptosis and induces apoptosis upon pro-NGF binding. Propeptides have a high-affinity to 
binding to p75 and have a low-affinity in binding to Trk receptors [Kliemannel et al. 2006, 
Pagadala et al. 2006]. Upon injury or neurodegenerative diseases, p75 is activated and promotes 
neuronal apoptosis and axonal degeneration to protect and repair [Yaar et al. 1997, Kraemer et al 
2014, Meeker and Williams 2015]. Mature sequences bind to Trk receptors with high affinity to 
promote neuronal survival, which is needed in neurodegenerative diseases [Lu et al. 2005]. Each 
neurotrophin binds with a specific Trk receptor: NGF to TrkA, BDNF to TrkB, and NT-3 to TrkC 
[Hauburger et al. 2007].  
The high-affinity and the low-affinity receptor complex dimerizes once a neurotrophin 
binds to its receptors [Sun & Davies 1995]. All neurotrophins are capable of binding to p75. If 
pro-peptides are not cleaved after renaturation, then the neurotrophins will have an affinity for 
p75. The true purpose of propeptides is still unknown. Previous works suggest propeptides may 
elicit neuronal survival; the area of synaptic plasticity and regulation is still emerging [Lu et al. 
2005, Buttigieg et al. 2007]. Pro-sequences are known for assisting in the folding of the mature 
region of cysteine knot growth factors such as TGFβ1 [Gray and Mason 1990], NGF [Rattenholl 
et al. 2001], and NT3 [Pagadala et al. 2006] into bioactive dimers. Drs. Rainer Rudolph, Elisabeth 
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Schwarz, and colleagues have done extensive works on the unfolding and folding mechanisms of 
nerve growth factor. Although pro-sequence NGF (pro-NGF) and mature-NGF (NGF) unfold 
slowly under similar conditions [Kliemannel et al. 2006], pro-NGF has an enhanced folding yield 
when compared to mature NGF [Rattenholl et al. 2001]. Pro-sequence NGF stimulates oxidative 
folding and contributes to the formation of the cysteine knot (2 disulfide bridges with a third bridge 
passing through the other 2) [Rattenholl et al. 2001, Hauburger et al. 2007]. Pro-sequence NT3 
(pro-NT3) can also assist in the oxidative folding of NGF despite the low homology of pro-NGF 
and pro-NT3 [Hauburger et al. 2007]. Aggregation during refolding occurs both in the pro-
sequence and mature-sequence. It is possible the pro-sequence acts as a shield from extensive 
aggregation [Rattenholl et al. 2001]. To decrease the level of aggregation during refolding, an ELP 
fusion tag can be added to the mature sequence [Johnson and Koria 2016, Leonard 2016]. In doing 
so, the sequence of that elastin-like polypeptide is capable to be designed to ensure reduced 
aggregation [Christensen et al. 2009].  
4.2 Choosing the Right Elastin-Like Polypeptide Sequence  
Designing an ELP is beneficial for the protein purification of recombinant proteins that do 
not retain a high concentration of themselves at the tumor site or site of injury [Kowalczyk et al. 
2014]. Manipulating the ELPs stimulus responsive behavior, mainly the transition temperature 
(Tt), provides efficient drug delivery in cancer therapy [McDaniel et al. 2010, Iglesias 2016], 
wound healing [Koria et al. 2011, Yuan 2016], and several other biomedical therapeutics 
[Kowalczyk et al. 2014]. The transition temperature is affected by the amino acid length, 
hydrophobicity, concentration of ELP in the solution, and molecular weight. The amino acid 
sequence and a high molecular weight promote self-assembly of an ELP or ELP fusion to a higher 
ordered nanostructure [Kowalczyk et al. 2014, Qin et al. 2016, Yuan 2016]. High ordered 
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nanostructures are stabilized by hydrophobic interactions [Kowalczyk et al. 2014]. These 
nanostructures can be triggered by a temperature higher than the ELP’s LCST. The longer the ELP 
length, the higher the hydrophobicity, the lower its Tt. Incorporating a hydrophobic amino acid, 
such as leucine, in the guest residue motif may allow transiting at physiological temperatures. Polar 
and charged amino acids, such as lysine, will increase the transition temperature [Christensen et 
al. 2013, Yuan 2016]. High heat can denature the protein so increasing the ionic strength is needed 
to trigger the phase transitioning property [Hassouneh et al. 2010]. Charged ELP sequences are 
more salt-sensitive than uncharged ELP sequences and high ionic concentrations will assist with 
triggering the inverse phase transition property during purification [Trabbic-Carlson et al. 2004b].  
4.3 Protein-Dependent Solubilization  
The primary goal of this project was to determine solubility parameters of neurotrophin 
elastin-like polypeptide (N-ELP) fusions after expression. Solubility as well as functionality was 
taken into consideration when choosing the ELP design. ELPs are a therapeutic peptide and can 
trigger cell proliferation when repair is needed. Mitogenic activity is triggered by the hydrophobic 
or charged guest residues in the ELP motif; so we incorporated them into the ELP sequences. 
Neurotrophins, specifically NGF and BDNF, were fused to the ELP sequences; 
(VPGVGVPGVGVPGKGVPGVGVPGVG)10, (VPGVGVPGVGVPGLGVPGVGVPGVG)10, 
(VPGVG)40(VPGVGVPGVGVPGCGVPGVGVPGVG)2 (V40C2), and (VPGVG)50 which is 
labeled as K10, L10, V40C2, and V50 respectively. 
4.3.1 Materials and Methods  
4.3.1.1 Synthesis of Genes Encoding Neurotrophin-ELP Fusion Proteins  
The PUC57 plasmid containing the gene encoding recombinant human NGF (UniProtKB-
P01138, Ser122-Ala241) and recombinant human BDNF (UniProtKB-P23560, His129-Arg247) 
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were purchased from GenScript for this study. The PUC19 plasmid containing the elastin cassette 
V40C2 has been described previously [Koria et al. 2011]. Three PUC19 plasmids containing the 
elastin cassettes K10, L10, and V50 have been described previously [Yuan 2016]. We used PflMI 
and BglI enzymes to excise the gene fragment encoding recombinant NGF or BDNF from the 
PUC57 plasmid. The excised gene fragments were cloned in frame in the plasmid containing the 
elastin cassette to create a gene encoding, either NGF-V40C2, NGF-V50, NGF-L10, NGF-K10, 
BDNF-V40C2, BDNF-V50, BDNF-K10, or BDNF-L10 as described previously [Meyer and 
Chilkoti 2002, Koria et al. 2011, Yuan 2016]. The gene encoding the fusion proteins was then 
excised from the PUC19 plasmid and inserted into the expression plasmid pET25b+ for protein 
expression.  
4.3.1.2 Expression of Neurotrophin-ELPs as Soluble and Insoluble Proteins  
The expression vector pET25b+ containing NGF-ELP (NGF-V40C2, NGF-V50, NGF-
L10, or NGF-K10) or BDNF-ELP (BDNF-V50, BDNF-K10, or BDNF-L10) was transformed into 
E.coli BLR (DE3) cells through heat shock at 42◦C. A starter culture of 15mL was then inoculated 
overnight and added to a 200mL culture the next day. The 200mL culture was then propagated 
overnight. The next day, bacterial cells were harvested by centrifugation (3000g, 20 minutes) at 
4◦C. The bacterial cells were then re-suspended in PBS. The bacterial cells were lysed by sonic 
disruption on ice (3 cycles, 50% amplitude, and 30 seconds on/off). The solution was centrifuged 
(20,000g, 15 minutes) and the pellet containing the inclusion body protein was collected and re-
suspended in 8M Urea while the supernatant was kept for analysis. The cell lysates and inclusion 
body pellets of NGF-ELP and BDNF-ELP proteins were then prepared for Western Blot analysis 
and stored at -20⸰C for later analysis.   
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4.3.1.3 Detection of Neurotrophin-ELPs 
The solubility of recombinant proteins were analyzed by electrophoresis on a 15% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. 
Western-blotting was performed with NGF antibody (Cell Signaling, 1:1000) or BDNF antibody 
(R&D Systems, 1:100).  
4.3.2 Results  
4.3.2.1 PBS is Capable of Solubilizing BDNF-ELPs after Protein Expression but Needs 
Assistance to Solubilize NGF-ELPs 
This study investigated whether charged or hydrophobic ELP sequence would reduce the 
possibility of neurotrophins forming inclusion bodies. To increase solubility of Neurotrophin-ELP 
fusion proteins, neurotrophins (NGF and BDNF) were fused to different sequences of ELP (K10, 
L10, V50 and V40C2) to reduce the possibility of aggregation during protein expression. Proteins 
with disulfide bridges are prone toward inclusion body formation. Most IBs require denaturation 
for solubilization, leaving the proteins vulnerable for aggregation during the unfolding and 
refolding process. NGF-ELPs were not soluble in PBS despite changing the ELP sequence. 
However, BDNF-ELPs were soluble in PBS. The lack of solubility of NGF-ELPs in PBS 
demonstrate a structural incompatibility between neurotrophins despite their similarity in sequence 
homology, size, and function. 
Three samples were taken: the first sample was of the supernatant of the re-suspended 
bacterial pellet in 1X PBS prior to sonication; the second sample was the cell lysate after sonication 
and centrifugation; the third sample was the insoluble aggregate (IB protein) and was solubilized 
in 8M Urea. BDNF-ELPs were found in both the cell lysate and IB protein (sample 2 and 3, 
respectively). NGF-ELPs were found only in the IB protein (sample 3). There was no protein found 
91 
in sample 1, suggesting that the protein may be trapped in the periplasmic membranes and 
cytoplasm. Finding BDNF-ELP in sample 2 supports that sonication releases soluble protein from 
bacterial cells by disrupting the membranes. With NGF and BDNF sharing a high sequence 
homology (Figure B.1), it was expected for them to behave somewhat similarly. However, it was 
known that NGF is one of the harder CKGFs to work with. Future studies must be conducted to 
pinpoint the conformational difference of NGF and BDNF to determine why NGF is more prone 
to aggregation than other neurotrophins and super family members. 
4.4 Discussion and Summary  
In this study, N-terminal (ELP-protein) versus C-terminal (protein-ELP) ELP fusion was 
taken into account when designing the ELP sequences. Redesigning the ELP or fusing an ELP to 
the N-terminus of a neurotrophin may increase the protein solubility. This idea is centered on the 
assistance pro-sequences offer in unfolding and refolding; if the ELP sequence was to mimic the 
critical amino-acids of a neurotrophin's pro-sequence then it may be easier to unfold and refold as 
well as to reduce aggregation. The advantage would be that we would not have to remove the ELP 
tag as we would the pro-sequence. A neurotrophin's pro-sequence contains cysteines that allow for 
intermolecular assistance with protein folding [Rattenholl et al. 2001]. V40C2 is a hydrophobic 
ELP sequence and contains 2 cysteines; it was believed the cysteine design could help facilitate 
folding of the neurotrophins like their pro-sequences.  
Hassouneh et al. have witnessed a high yield of protein when a short peptide of ELP, less 
than 5kDa, is fused to the N-terminus of the protein. However, a short VPVG motif has been shown 
to not provide the ability to render the fusion insoluble when stimulated [Yuan and Koria 2016]. 
Because ELP-protein constructs express a low amount of soluble ELP protein, we may not need 
to work with denaturants [Christensen et al. 2009]. However, previous works in our lab have 
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demonstrated soluble N-ELPs can be expressed which suggests ELPs do increase the solubility of 
a neurotrophin. This idea may be successful, but according to researchers in this field, Christensen 
et al. found low expression of soluble protein and hardly any inclusion body formation with N-
terminal fusion. Increasing the expression of soluble protein can be conducted by adding osmolytes 
and amino acids. Sorbitol and arginine have been shown to improve the presence of soluble 
proteins when added to the growth medium. Insoluble fractions still occur; however, if sorbitol or 
arginine are used in the growth media then there will be more soluble fractions produced alongside 
insoluble fractions [Prasad et al. 1998].  
BDNF-ELPs develop soluble fractions and insoluble fractions during expression. BMP-2-
V40C2, EGF-L10, and EGF-V40C2 are soluble in PBS and fold efficiently in the absence of pro-
sequences [Leonard 2016, McCarthy et al. 2016, Leonard and Koria 2017]. Extensive studies 
should be conducted to see if the solubility of N-ELPs in PBS may have to do with the 
concentration of the IB pellet in PBS, the pH of PBS, time limit of solubilization, temperature, etc. 
The conflicting results of BDNF-ELPs being soluble in PBS after expression and NGF-ELPs not 
demonstrating solubility in PBS within the parameters used emboldens the scientific community's 
reasons for moving away from working with NGF and focusing on BDNF. However, protocols for 
expressing and purifying IB proteins must be adjusted for each protein: to say the NGF-ELPs are 
not soluble in PBS is not accurate until all scenarios are studied.  
Previously in Chapter 2 it was demonstrated that the NGF-V40C2, BDNF-V0C2, and 
NGF-V40C4 were present in the washing buffer and cell lysate. The washing buffer contains 
glycerol, Tris, Triton X-100, DTT, and EDTA; whereas the lysis buffer contains the contents of 
the washing buffer, lysozyme, and NaCl. Glycerol enhances hydrophobic interactions, stabilizes 
protein, and decreases the surface tension of water by increasing its viscosity [Alibolandi and 
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Mirzahoseini 2011]. These properties suggest that, if appropriate conditions are applied, there is a 
possibility for glycerol to solubilize IBs in conjunction with these compounds. Gonzalez-
Villasenor vaguely states that stabilizing compounds like glycerol can be included in the 
solubilizing solution but this researcher does not state that glycerol is directly responsible for 
solubilizing the IB pellet [Gonzalez-Villasenor 2005]. Triton X-100 removes the bacterial 
membranes which may release the soluble proteins from the inclusion body aggregates that are 
within the E.coli cells without disrupting the native structures [Makino et al. 1973]. Detergents 
like Triton X-100 reduce the surface tension in water and reduces aggregation in recombinant 
proteins [Lebendiker and Danieli 2013]. Salts typically increase the water tension and bind more 
tightly with water, a reaction which reduces the interaction of the protein in water. This may be 
why NGF-ELPs are soluble in the washing and lysing buffers and not in PBS. Triton X-100 has 
been demonstrated to increase a protein’s yield [Shimamoto et al. 1998, Tao et al. 2010] and has 
solubilized soluble envelope proteins in cytoplasmic membranes [Schnaitman 1971]. Schnaitman 
also demonstrated an insoluble fraction of proteins. His work may be the antecedent of studying 
the presence of native-like structures in IB proteins. Lysozyme and sonication have also been used 
to release protein from inclusion body pellets, further suggesting that all may act together to release 
soluble proteins [Peternel and Komel 2010, Rodríguez-Carmona et al. 2010, Singh et al. 2015, 
Wingfield 2015]. The washing and lysing buffers work in conjunction to extract the soluble 
proteins from inclusion body pellets. To separate the soluble protein from the bacterial 
contaminants, salting out the soluble protein may be the method of choice. Salts like ammonium 
sulfate or sodium chloride can trigger the ELP’s phase transitioning property and separate the 
soluble proteins from the E.coli lysate at high speed centrifuge [Zhang et al. 2009, Alibolandi and 
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Mirzahoseini 2011, Hassouneh et al. 2011, Leonard and Koria 2017]. Also, the addition of free 
ELPs to the cell lysate may increase the salting out of the target protein [Christensen et al. 2007]. 
Many researchers have noted that IBs may be aggregated oligomers that are comprised of 
unfolded, partially folded, and native-like structures. Previous studies have demonstrated that large 
amounts of properly partial folded protein are trapped in IB protein [Prasad et al. 1998, Carrio 
2000, Peternel et al. 2008, Villaverde 2012]. Additionally, accounts of functional activity, such as 
the glowing of a GFP chromophore, in IB pellets have been reported [Tsumoto et al. 2010]. The 
functional activity of GFP in IB proteins provide further evidence that recombinant proteins can 
be partially folded or in a native-like structure; further evidence shows IBs may contain protein in 
alpha helices and beta sheets [Prasad et al. 1998, Carrio et al. 2000, Peternel et al. 2008, Wang 
2009, Villaverde 2012, Singh et al. 2015]. Non-denaturing solubilization of IB proteins has been 
conducted; these studies show that sarkosyl (N-lauroyl sarcosine), propanol, DMSO, and arginine 
produce functional protein [Peternel et al. 2008, Tao et al. 2010, Tsumoto et al. 2010, Massiah et 
al. 2016]. Organic solvents like propanol can interact with proteins and stabilize their secondary 
and tertiary structures [Singh et al. 2015]. However, it has been shown that ELPs phase 
transitioning property disappears in organic solvents [Simnick et al. 2007]. Subsequently, a 
problem arises because the ELP phase transition property is what we use to purify the 
neurotrophin-ELP fusions and what we will use to deliver the N-ELP fusions to the site of injury; 
explaining why arginine is a more promising non-denaturing agent. Arginine solubilization is 
comparable to Dr. Panda's mild solubilization and is capable of recovering a high yield of protein; 
also, it should be noted that at high temperatures the solubilization of the IB protein increased 
[Tsumoto et al. 2010]. This notion further suggests using denaturants will not be necessary to 
solubilize an IB protein in the future; which means there will be less need of renaturing the protein 
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and will ultimately decrease production time and increase the protein yield. However, it must be 
mentioned that proteins that contain disulfide bridges, like CKGFs, are the least likely to be able 
to produce a high level of soluble protein. The proteins reported to have successful solubilization 
in non-denaturing conditions had no disulfide bonds or the disulfide bonds the proteins did have 
were not essential to folding [Tsumoto et al. 2009]. 
Dealing with aggregation while unfolding and refolding a protein is a headache. I can attest 
that it has been the most frustrating thing I have ever done. Other researchers also note the 
difficulty of recovering a high yield of protein [Rudolph and Lilie 1996, Pina et al. 2014]. Due to 
this difficulty, the focus should be shifted to non-denaturing solubilization for IBs. L-arginine is 
the most promising agent to use due to the purification process of ELP fusions. To remove the 
organic solvents, dilution and column chromatography are conducted [Peternal et al. 2008, Tao et 
al. 2010]. Column chromatography is not the method of purification that is cost-efficient [Trabbic-
Carlson et al. 2004]. Additionally, I want to utilize the phase transition property of ELP to purify 
the fusions via inverse transition cycling and reduce the current volume of solvents needed to 
produce a pure bioactive protein. ELP purification will reduce costs in the lab and reduce the stress 
of having to refold proteins while manually using drop-wise pulsatile renaturation. Because of the 
expression of soluble proteins in IB proteins, we may not need to be concerned with the N-terminal 
fusion of ELPs to the target protein. Finding an effective solubilizing protocol of IB protein is 
essential to recovering a high yield of protein after expression. In addition, modeling the protein 
computationally may reduce the stress and cost of benchwork [Zhang et al. 2009]. Modeling with 
the knowledge of ELP length and amino acid properties will assist in developing the perfect ELP 
construct for increasing N-ELP solubility.  
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Figure 4.1 Soluble and insoluble expression of N-ELPs. A) Soluble and insoluble proteins were 
expressed. The expressed media were centrifuged and the pellet was solubilized in 1X PBS 
(Sample 1 – no reactivity). The mixture was then sonicated and centrifuged. The cell lysates are 
considered sample 2 and are represented in A1-A4. The pellet was solubilized in 8M Urea and is 
represented by A5-A8. The expression of BDNF-ELP was confirmed by western blot using an 
antibody reactive to BDNF. Where, 1 – BDNF-K10 cell lysate, 2 – BDNF-L10 cell lysate, 3 – 
BDNF-V40C2 cell lysate, 4 – BDNF-V50 cell lysate, B – Blank, 5 – BDNF-K10 IB pellet, 6 – 
BDNF-L10 IB pellet, 7 – BDNF-V40C2 IB pellet, 8 – BDNF-V50 IB pellet. Soluble and insoluble 
proteins were expressed. The expressed media were centrifuged and the pellet was solubilized in 
1X PBS (Sample 1 – no reactivity). The mixture was then sonicated and centrifuged. The cell 
lysates are considered sample 2 (no reactivity). The pellet was solubilized in 8M Urea and is 
represented by B1-B4. The expression of BDNF-ELP was confirmed by western blot using an 
antibody reactive to NGF. Where, B) 1 – NGF-K10 IB pellet, 2 – NGF-L10 IB pellet, 3 – NGF-
V40C2 IB pellet, 4 – NGF-V50 IB pellet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
101 
 
 
 
 
 
CHAPTER 5. SUMMARY, CONCLUSION, AND FUTURE WORK  
In this study, recombinant DNA technology was used to fuse NGF and BDNF with 
different ELP sequences for fusion expression and purification without the need of 
chromatography. N-ELP fusions formed inclusion body proteins during expression and were 
denatured to solubilize the aggregated proteins.  Results have shown BDNF-ELPs produce soluble 
and insoluble fractions during expression. During expression of N-ELP fusions form inclusion 
bodies (IBs) and urea was used to denature and solubilize the insoluble aggregates. Urea created a 
bridge between the water molecules and ELP, which allowed solubilization of the inclusion bodies. 
Previous works have shown that not all proteins that form inclusion bodies must be denatured by 
urea and that proteins that form IB proteins also express soluble fractions. BDNF-ELPs produce 
soluble and insoluble fractions during expression. It is believed that NGF-ELPs produce soluble 
and insoluble fractions as well; however, PBS is not efficient enough to solubilize the NGF-ELP 
proteins at the current state. Therefore, further investigations must be done because proteins are 
method specific, not one method works for all proteins. 
Denaturing the inclusion body protein was the commonly used method because the 
scientific community heavily believes the IB protein is full of unfolded and misfolded protein. The 
belief that the IB protein is comprised of partially folded protein aggregated with itself in the 
bacterial cell components is now widely accepted. IBs are no longer a curse to researchers and are 
now being seen as a protector of recombinant proteins within the IB aggregates from bacterial 
machinery Protein that make it out of the cytosol to the periplasmic membrane are expressed as 
the soluble proteins. Purifying the soluble expressed proteins would not require denaturants which 
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means there would be no unfolding and refolding process. Therefore, aggregation would be 
reduced and protein recovery would be increased. It has been shown that proteins can maintain 
their secondary structures in the IB pellet. Since IB proteins are being formed by non-covalent 
hydrophobic interactions strong denaturants are not needed to solubilize aggregates [Singh and 
Panda 2005]. It is possible to solubilize the pellet in arginine or other compounds. The inclusion 
body protein community does not focus its research on CKGFs and I understand why; however, 
this knowledge should be seriously considered and researched. Solubilizing with strong 
denaturants should be pulled back and mild solubilization or non-denaturing solubilization should 
be the face of IB protein solubilization.  
Bringing recombinant proteins to market is difficult because they lack bioavailability, have 
short in vivo half-lives, and require high manufacturing costs. Fortunately, elastin-like peptide 
(ELP) fusions increase recombinant protein solubility and promote therapeutic delivery and 
efficacy. Therefore, fusing recombinant proteins with genetically encodable ELPs will increase 
bioavailability and enhance in vivo solubilization, as well as provide a cost-effective method for 
purification without the need for chromatography.  
Studying the unfolding of N-ELP fusions will determine if a protein aggregates as it 
unfolds. If it aggregates, then it is deemed irreversible, and will have a limited or diminished 
bioactivity and/or solubility. However, denaturants, additives, and osmolytes can be added to 
decrease aggregation during unfolding and refolding, thereby allowing for protein reversibility. 
Elastin-like polypeptide fusion tags increases the solubility of Brain-derived neurotrophic factors; 
however, they were less effective with fusing to nerve growth factor at the current parameters. 
Addressing the solubility issues of N-ELP fusion proteins developed from inclusion bodies will 
impact the development of a stable biopharmaceutical formulation that can reach the market. 
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However, if the buffer conditions are not optimal, the drug’s efficacy will be decreased. 
Knowledge of the proper buffer and storage conditions will be important for long-term stability 
(shelf-life) of the protein.  
The novelty of this project lies in the purification technique for the ELP fusions, their 
thermal behavior and the neurotrophin-ELP fusions themselves. The intellectual merit of this 
project is its investigation of recombinant functional biomaterial. Future studies on the unfolding 
and refolding of these proteins will give insight into how a denaturant may affect the stimuli-
responsive property of ELPs as well as how a denaturant may affect the conformational stability 
of N-ELP fusions. It is essential to investigate whether using a denaturant to purify the proteins 
will change the protein’s conformation. Studying the conformational stability of ELP fusion 
proteins will help determine their suitability for drug delivery. ELPs provide multiple avenues of 
drug delivery and can self-assemble into nanostructures, are used as injectable hydrogels or even 
as electrospun nanofibers which can provide a unique topographical scaffold surface. Elastin-like 
peptide (ELP) fusions promote therapeutic delivery and efficacy. Fusing recombinant proteins 
with genetically encodable ELPs will increase bioavailability, enhance in vivo solubilization, as 
well as provide a cost-effective method for purification without the need for chromatography.   
Furthermore, investigating the solubility parameters of ELP and N-ELP fusions will have 
a broader impact in the field of biophysics, protein science, protein engineering, and neuroscience. 
In addition, there will be a better understanding of the effects denaturants have on the 
unfolding/folding process. The knowledge gained through these experiments will advance 
neurotrophin drug design which will address the challenges of treating neurodegenerative diseases.  
Further investigations must be done to determine the best environment for NGF-ELP 
solubility. Once done, characterizing these N-ELP proteins may open up a door to understanding 
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the conformational stability of the fusion proteins and increasing the solubility, which may aid in 
the usage of these proteins as injectable hydrogels to treat spinal cord injury, thereby having a 
broad impact in the field of protein engineering, biophysics, and neurological treatments.  
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Appendix A. List of Abbreviations  
BDNF  Brain-derived neurotrophic factor  
BMP-2 Bone morphogenetic protein 2  
C  Cysteine  
Cdna  Complimentary Deoxyribonucleic acid  
CKGF  Cysteine knot growth factor  
CKGF-ELP  Cysteine knot growth factor-Elastin like polypeptide  
DLS  Dynamic light scattering  
DNA  Deoxyribonucleic acid  
EDTA  Ethylenediaminetetraacetic acid  
EGF  Epidermal growth factor  
ELP  Elastin like polypeptide  
G  Glycine  
GAPDH Glyceraldehyde 3-phosphate dehydrogenase  
GSH  Reduced glutathione  
GSSG  Oxidized glutathione  
ITC  Inverse temperature cycling  
K  Lysine 
kDa  Kilo Dalton  
L  Leucine  
LCST  Lower critical solution temperature  
NaCl  Sodium Chloride 
NGF  Nerve growth factor  
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NH4Cl  Ammonium Chloride 
(NH4)2SO4 Ammonium Sulfate 
NT-3  Neurotrophin-3  
P  Proline  
PAGE  Polyacrylamide gel electrophoresis  
PBS  Phosphate buffered saline  
PC12  Pheochromocytoma Cells 12  
PCR  Polymerase chain reaction  
PDGF  Platelet-derived growth factor  
RNA  Ribonucleic acid  
Rt  Room temp./Room temperature 
RT-PCR Real time-Polymerase chain reaction  
SDS  Sodium dodecyl sulfate  
Trk  Tyrosine receptor kinase or Tyrosine kinase or Tropomyosin receptor kinase  
Tt  Transition temperature  
V  Valine  
VEGF  Vascular endothelial growth factor  
X  Guest amino acid residue  
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Appendix B. Supplementary Tables and Figures 
 
Table B.1 ELP Sequences and Characterization 
ELP Sequence Characterization 
V40C4 (VPGVG)40(VPGVGVPGVGVPGCGVPGVGVPGVG)4 Neutral 
V40C2 (VPGVG)40(VPGVGVPGVGVPGCGVPGVGVPGVG)2  Neutral 
V50 (VPGVG)50  Neutral 
L10 (VPGVGVPGVGVPGLGVPGVGVPGVG)10  Hydrophobic, Neutral 
K10 (VPGVGVPGVGVPGKGVPGVGVPGVG)10  Hydrophilic, Positive 
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Table B.2 Neurotrophin-ELP Molecular Weights 
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Figure B.1 Neurotrophin Sequence Homology. The sequence homology between BDNF and NGF was generated through UNIPROT 
FASTA using the human sequence. Where the pink highlights represent the mature sequence of BDNF and NGF, the green represents 
the location for disulfide bonds, and the symbols .:* (period, colon, asterisk) represent the similarity between the BDNF and NGF 
sequence from least to homologous, respectively. 
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Figure B.2 Neurotrophin-ELP expression and purification. Recombinant proteins linked to elastin 
like polypeptides can be expressed in bacteria and purified to high homogeneity by utilizing the 
ELPs’ reversible inverse phase transitioning property.  
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